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ABSTRACT Cerebral	 autosomal	 dominant	 arteriopathy	 with	 subcortical	 infarct	 and	leukoencephalopathy	 (CADASIL)	 is	 caused	 by	 a	 mutation	 on	 the	NOTCH3	 gene.	 The	pathological	 driver	 behind	 this	 disease	 is	 the	 loss	 of	 vascular	 smooth	 muscle	 cells	(VSMCs)	in	small	blood	vessels	and	subsequent	fibrotic	thickening	of	the	vessel,	causing	stenosis.	Although	a	great	deal	of	knowledge	has	been	accumulated	through	CADASIL	research,	 more	 information	 is	 needed	 to	 fully	 grasp	 the	 pathological	 mechanisms	 as	well	 as	 understand	 disease	 progression.	 We	 have	 focused	 on	 the	 effects	 of	NOTCH3	mutation	on	VSMCs	and	identified	several	novel	actors	in	disease	progression.		In	our	initial	study,	we	investigated	factors	playing	a	role	in	the	VSMC	proliferative	rate.	We	found	that	VSMCs	carrying	a	CADASIL	mutation	express	higher	levels	of	TGFβ.	This	elevated	cytokine	secretion	by	CADASIL	VSMCs	had	an	inhibitory	proliferative	effect	on	not	 only	 these	 cells,	 but	 also	 cells	 in	 their	 vicinity.	 This	 phenotype	 was	 rescued	 by	adding	 neutralizing	 TGFβ	 antibody	 to	 the	 growth	 media,	 which	 increased	 CADASIL	VSMC	 proliferation	 rate	 to	 that	 of	 control	 VSMCs,	 while	 having	 a	 minimal	 effect	 on	control	VSMC	proliferation	rate.		One	of	 the	 initial	 events	 in	CADASIL	disease	progression	 is	NOTCH3	aggregation	 and	accumulation.	In	our	next	study,	we	focused	on	degradation	of	aggregated	NOTCH3	via	autophagy	processes.	After	confirming	that	NOTCH3	is	aggregated	and	accumulated	in	our	cell	line,	we	further	tested	the	autophagy	process	in	these	cells.	We	discovered	that	the	 autophagy	 process	 in	 CADASIL	 VSMCs	 is	 interrupted	 and,	 upon	 further	investigation,	 found	 that	 this	 could	 be	 due	 to	 a	 dysfunction	 in	 fusion	 of	 the	autophagosome	and	lysosome.			Next,	 we	 investigated	 the	 nutritional	 requirements	 in	 CADASIL	 VSMCs	 compared	 to	control	 VSMCs.	 One	 of	 the	 most	 readily	 available	 forms	 of	 nutrients	 in	 myocytes	 is	glucose.	 Hence,	 we	 examined	 glucose	 transporter	 expression	 in	 CADASIL	 VSMCs	compared	 to	 control	 VSMCs.	 CADASIL	 VSMC	 glucose	 transporters	 were	 significantly	down	 regulated	 and	 this	 down	 regulation	 had	 a	 negative	 functional	 effect	 such	 that	CADASIL	 VSMCs	were	 unable	 to	 take	 up	 glucose	 as	 avidly	 as	 control	 VSMCs.	 Adding	insulin	to	the	media	only	moderately	increased	glucose	uptake	in	CADASIL	VSMCs	since	Glut	 4	 was	 the	 only	 insulin-dependent	 glucose	 transporter	 that	 was	 down	 regulated	(other	 glucose	 transporters	 were	 also	 down	 regulated,	 but	 they	 were	 insulin-independent).	VSMCs	 in	 CADASIL	 are	 frail	 and	 less	 resistant	 to	 stress.	 Based	 on	 this	 fact,	 we	hypothesized	 that	 they	 may	 secret	 inflammatory	 cytokines	 and	 thereby	 affect	 their	neighboring	 cells	 in	 paracrine	 fashion.	 Measuring	 inflammatory	 cytokine	 gene	expression,	we	discovered	that	most	of	them	were	up	regulated,	which	translated	to	an	increased	amount	of	protein	synthesis.	In	this	study,	we	have	implicated	inflammation	
as	 a	 pathological	 driver	 in	 CADASIL.	 Dampening	 of	 this	 inflammatory	 response	may	slow	the	rate	of	VSMC	loss	and,	consequently,	disease	progression.	
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1 INTRODUCTION 
1.1 OVERVIEW OF CADASIL Cerebral	 autosomal	 dominant	 arteriopathy	 with	 subcortical	 infarct	 and	leukoencephalopathy	 (CADASIL)	 is	 a	 genetic	 disease	 that	 is	mapped	 to	 chromosome	19q13	 [1,	 2].	 This	 disease	 was	 described	 as	 the	 presentation	 of	 ischemic	 strokes	regardless	of	a	history	hypertension	and	hyperlipidemia,	which	made	 it	unique	when	compared	 to	 the	 causes	 of	 stroke	 previously	 described	 [1,	 2].	 Although	 CADASIL	genetics	were	only	recently	defined,	this	disease	could	have	been	discovered	as	early	as	1955	when	 van	Bogaert	 described	 a	 “Binswanger’s	 disease	with	 rapid	 course	 in	 two	sisters”	[2],	but	of	course	the	methods	to	diagnose	CADASIL	did	not	exist	at	that	time.	Clinical	symptoms	may	vary	between	familial	lines	and	based	on	the	mutation	site,	but	the	 core	 clinical	 manifestations	 consist	 of	 migraine	 with	 aura,	 subcortical	 ischemic	attacks,	 mood	 swings	 or	 disturbance,	 apathy,	 and	 (perhaps	 the	 most	 noticeable)	cognitive	decline.	CADASIL	starts	early	 in	 life,	with	migrainous	symptoms	manifesting	as	early	as	the	teenage	years.	Disease	progression	is	slow.		Because	 of	 its	 ambiguousness,	 the	 prevalence	 of	 this	 disease	 is	 hard	 to	 predict	accurately;	 however,	 reports	 have	 suggested	 that	 the	 prevalence	 is	 2-4	 persons	 per	100,000	 [3-5].	 Although	 the	 majority	 of	 data	 regarding	 prevalence	 originates	 from	Europe,	 non-European	 countries	 are	 increasingly	 reporting	 cases	 of	 CADASIL,	suggesting	that	current	prevalence	estimations	will	increase	with	better	diagnostic	tools	and	a	better	understanding	of	the	course	of	the	disease.	In	Sweden,	there	are	currently	over	100	diagnosed	CADASIL	patients,	with	belief	that	an	additional	300-400	cases	exist	that	 are	 either	 unreported	 or	 misdiagnosed.	 Currently	 there	 are	 over	 150	 NOTCH3	mutations	identified	that	cause	CADASIL	[6].			
1.2 CLINICAL INSIGHT 
1.2.1 Blood Vessels  The	human	brain	 is	 supplied	with	blood	via	several	major	blood	vessels,	 including	as	the	 vertebral,	 common,	 internal	 and	 external	 carotid	 arteries	 [7].	 These	major	 blood	vessels	 for	 the	 circle	of	Willis	 and,	 therefrom,	 three	 cerebral	 arteries	originate.	These	arteries	 further	 branch	 into	 smaller	 arteries	 that	 penetrate	 deep	 within	 the	 white	matter.	Most	blood	vessels	in	the	brain	run	straight;	however,	upon	entering	the	white	matter	 they	 start	 to	 coil,	 branch	off	 and	 loop	 [8].	While	 the	 gray	matter	 is	 composed	mainly	 of	 neuronal	 cell	 bodies,	 axons,	 dendrites,	 and	 glial	 cells,	 the	 white	 matter	consists	 mostly	 of	 dense,	 myelinated	 axons	 [9].	 Regardless	 of	 anatomical	 structure,	almost	all	cerebral	small	vessels	have	a	similar	histological	phenotype.			
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Cerebral	 blood	 vessels	 have	 a	 three-layer	 structure.	 The	 innermost	 layer,	 the	 tunic	
intima,	 is	composed	of	a	single	layer	of	endothelial	cells	(ECs)	held	together	by	a	tight	cellular	 junction	 and	 an	 internal	 elastic	 lamina	 (Figure	 1).	 In	 cardiovascular	 disease,	damage	to	these	ECs	can	cause	infiltration	of	lymphocytes	leading	to	plaque	formation.	The	 middle	 layer,	 the	 tunica	 media,	 is	 comprised	 of	 smooth	 muscle	 cells	 (SMCs),	fibroblasts,	and	collagen	fibers.	The	number	of	layers	of	SMCs	depends	on	the	size	and	location	of	the	vessel.	For	example,	the	internal	carotid	arteries	can	have	as	many	as	20	layers	of	SMCs,	whereas	smaller	vessels	may	have	only	two	or	three	layers	of	SMCs.	The	outermost	 layer,	 the	 tunica	 adventitia	 or	 tunica	 externa,	 consists	 mostly	 of	 collagen,	fibroblasts,	and	associated	cells	[10].			
 
Figure 1: Illustrative representation of the three different layers of cerebral blood vessels.		
1.2.2 Cerebral Small Vessel Disease (SVD) The	 term	 small	 vessel	 disease	 (SVD)	has	 come	 to	 encompass	 a	 collection	of	 different	diseases	where	small	vessels	are	involved.	Some	of	the	diseases	fall	under	the	term	SVD	are	 coronary	 microvasculature	 disease	 (CMD),	 coronary	 artery	 disease	 (CAD),	 small	vasculature	vasculitis,	and	cerebral	small	vessel	disease.	Most	 investigation	 into	small	vessel	disease	has	been	focused	on	cerebral	small	vessel	diseases,	such	as	CADASIL.	In	fact,	SVD	has	nearly	become	synonymous	with	vascular	dementia	and	is	responsible	for	about	45%	of	dementia	cases	[11,	12].		Cerebral	blood	flow	plays	a	vital	role	in	cognition	and	functional	integrity	of	the	brain	and	cerebral	SVDs	are	connected	to	a	disruption	in	such	flow.	There	are	also	non-SVD	conditions	that	are	connected	to	disrupted	cerebral	blood	flow,	such	as	cardiac	arrest,	arrhythmias,	cardiac	failure	hypotension,	or	stenosis.	The	exact	mechanism	of	neuronal	damage	 following	 low	 perfusion	 is	 unknown;	 however,	 chronic	 hypoxia,	 oxidative	
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stress,	 and	 inflammation	 have	 been	 identified	 as	 contributing	 factors	 for	 cognitive	decline	 [7].	 It	 is	 interesting	 that	 hypercapnia	 (a	 hypoxic	 condition	 that	 results	 in	systemic	 vasodilation)	 does	 not	 increase	 cerebral	 blood	 flow	 but,	 on	 the	 contrary,	reduces	it	in	healthy	subjects	[13],	suggesting	that	treatment	of	cerebral	SVD	requires	a	different	 approach	 than	 peripheral	 SVDs.	 It	 is	 reasonable	 to	 speculate	 that	 chronic	hypoxia	 can,	 in	 turn,	 cause	 inflammatory	 cascades	 in	 the	 brain.	 Several	 pathological	studies	have	identified	elevated	levels	of	various	cytokines	and	adhesion	molecules	 in	the	hypoxic	brain.	Additionally,	post	mortem	studies	have	identified	activated	microglia	and	 reactive	 astrocytes	 in	 the	 brain	 tissue	 of	 individuals	 who	 have	 suffered	 from	hypoxia	[7].		Given	 that	 SVDs	 are	 multifactorial	 disorders,	 no	 single	 intervention	 is	 sufficient	 for	treating	 all	 types	 of	 SVD.	 CADASIL	makes	 a	 good	 disease	model	 to	 study	 SVD	 as	 the	underlying	 cause	 of	 CADASIL	 is	 known	 to	 be	 a	 mutation	 in	 the	 NOTCH3	 gene	 and	because	 other	 risk	 factors	 are	 not	 present	 –	 eliminating	 some	 of	 the	 complexities	associated	with	studying	other	types	of	cerebral	SVD.	It	is	noteworthy	that	the	same	risk	factors	 that	 apply	 to	CAD	and	CMD	can	exacerbate	CADASIL,	 albeit	CADASIL	patients	most	often	lack	any	such	risk	factors.			
1.2.3 Stroke Stroke	is	a	condition	in	which	the	blood	flow	to	a	portion	of	the	brain	is	disrupted.	This	disruption	 in	 blood	 supply	 results	 in	 a	 localized	 area	 of	 necrosis	 in	 the	 surrounding	tissue,	which	is	called	an	infarct.	In	clinical	terms,	a	stroke	event	in	the	brain	is	defined	as	(1)	an	acute	 focal	brain	dysfunction	 that	 lasts	more	 than	24	hours,	or	 (2)	an	acute	focal	brain	dysfunction	of	any	duration	if	computed	tomography	or	magnetic	resonance	imaging	 shows	 an	 infarction	 or	 hemorrhage	 that	 can	 be	 correlated	 to	 the	 patient’s	symptoms	[14].	Over	the	years,	advances	in	stroke	research	have	resulted	in	decreased	mortality,	 but	 the	 incidence	 of	 stroke	 has	 steadily	 increased.	 Although	 patients	 who	receive	 early	 treatment	 have	 good	 a	 chance	 of	 survival,	 their	 activities	 of	 daily	 living	generally	become	greatly	affected.		As	of	2010,	there	were	over	33	million	reported	cases	of	stroke	survivors,	representing	a	large	increase	since	1990	(about	18	million	cases)	[14].	This	increase	in	could	be	(at	least	 in	 part)	 due	 to	 an	 increase	 in	 the	 average	 lifespan,	 better	 diagnostic	 tools,	 and	increased	public	awareness	about	the	risk	factors	associated	with	stroke.	Hypertension,	atrial	 fibrillation,	 hypercholesterolemia,	 lifestyle	 choices	 (e.g.,	 cigarette	 smoking,	sedentary	lifestyle,	obesity,	etc.),	and	carotid	stenosis	are	among	a	growing	list	of	such	risk	 factors	 [15-17].	 Although	 there	 are	 several	 stroke	 subtypes,	 hemorrhagic	 and	ischemic	stroke	comprise	the	two	major	types.	
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1.2.4 Hemorrhagic stroke In	a	hemorrhagic	stroke	event,	the	blood	vessel	ruptures	and	its	contents	are	released	into	 the	 brain	 parenchyma.	While	 hemorrhagic	 stroke	 is	 less	 common	 than	 ischemic	stroke,	the	former	is	more	devastating	and	debilitating	[18].	The	risk	factors	associated	with	hemorrhagic	stroke	are	the	same	as	those	associated	with	ischemic	stroke,	but	the	underlying	cause	of	these	two	types	of	stroke	differs	greatly.	The	underlying	causes	of	hemorrhagic	 stroke	 include	 hypertension	 (the	 most	 common	 cause)	 followed	 by	cerebral	amyloid	angiopathy	CAA,	drug	use,	aneurysm,	and	previous	ischemia.			
1.2.5 Ischemic stroke Conversely,	in	an	ischemic	stroke	event,	the	vessel	does	not	leak	or	rupture;	it	becomes	blocked	 (or	 is	 narrowed	 to	 the	 extent	 that	 blood	 cannot	 flow	 freely).	 Moreover,	 the	cause	 of	 ischemic	 stroke	 can	 be	 linked	 to	 hypercholesterolemia,	 hypertension,	 and	cardiovascular	disease	(CVD).	Based	on	current	estimates,	SVD	is	responsible	for	about	20%	of	all	 ischemic	strokes	[11,	12].	 Ischemic	stroke	is	the	most	common	outcome	of	CADASIL	and	is	also	the	most	likely	driver	of	pathogenesis.	Although	CADASIL	patients	lack	 the	 conventional	 risk	 factors	 for	 vascular	 disease,	 they	 are	 prone	 to	 transient	ischemic	attacks.	These	events	occur	later	than	the	migraine	attacks,	with	a	mean	age	of	49	and	a	frequency	as	high	as	85%.	Most	of	these	attacks	are	subcortical	infarcts	with	subsequent	 lacunar	 syndrome	 (see	 Lacunar	 stroke).	 CADASIL	 patients	may	 have	 3-5	recurrent	 strokes	 over	 period	 of	 several	 years	 and	 this	 number	 increases	 with	 the	addition	 of	 hypertension,	 smoking,	 hypercholesterolemia,	 and	 other	 conventional	vascular	risk	factors.		These	recurrent	strokes	lead	to	ataxic	hemiparesis	(which	is	a	contralateral	weakness),	motor	 and/or	 sensory	 deficiency,	 dysarthria	 (difficulties	 formulating	 a	 coherent	sentence	or	other	 linguistic	difficulties),	urinary	dysfunction,	and	other	stroke-related	symptoms	[19-21].	About	20%	of	patients	suffer	 from	mood	disturbance,	with	apathy	being	the	most	common	complaint.	Other	mood	disturbances	associated	with	CADASIL	include	depression	with	occasional	manic	episodes,	which	is	easily	mistaken	for	bipolar	disease.	 It	 has	 been	 posited	 that	 the	 depression	 could	 originate	 from	 patients	experiencing	the	feeling	of	becoming	demented.			
	
1.2.6 Lacunar stroke In	 some	cases,	 the	necrotic	 tissue	 resulting	 from	a	 stroke	event	 is	 either	 removed	by	normal	bodily	processes	or	retracts,	leaving	an	empty	cavity	(a	lacuna)	that	is	visible	on	diagnostic	imaging	tools	as	a	black	space	(a	lesion).	These	so-called	lacunar	strokes	are	the	 result	 of	 the	 blockage	 or	 rupture	 of	 a	 single,	 small,	 deep,	 penetrating	 vessel.	 The	most	common	type	of	stroke	in	CADASIL	is	ischemic	lacunar	stroke.		
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There	 are	 four	 possible	 reasons	 proposed	 for	 lacunar	 infarcts:	 atheroma	 of	 parent	artery	or	perforating	arteriole,	 intrinsic	vessel	abnormality,	 and	emboli.	Based	on	 the	location	of	the	lesion	and	resulting	impairment,	lacunar	stroke	could	be	further	divided	into	 pure	 motor	 hemiparesis,	 pure	 sensory	 stroke,	 ataxic	 hemiparesis,	 sensorimotor	stroke	and	dysarthria	syndrome	[22].	Controversy	has	arisen	to	whether	lacunar	stroke	is	 different	 than	 cortical	 ischemic	 stroke.	 In	 most	 cases,	 lacunar	 stroke	 are	 in	 deep	penetrating	vessels	affecting	the	white	matter	and	the	cause	of	the	stroke	appears	to	be	intrinsic	cerebral	small	arteriolar	abnormality	while	cerebral	 ischemic	stroke	involves	emboli	 from	 larger	 vessels	 and	 the	 heart	 [23].	 Among	 all	 the	 risk	 factors	 involved	 in	stroke,	 hypertension	 emerges	 as	 one	 of	 the	 most	 important	 with	 regard	 to	 lacunar	stroke.	 However,	 in	 the	 clinical	 setting,	 hypertension	 in	 lacunar	 patients	 is	 not	correlated	to	severity	of	the	outcome	[24].		
1.2.7 Diagnosis of stroke   The	most	common	clinical	features	associated	with	stroke	are	neurological	deficiencies.	The	 most	 common	 symptoms	 are	 altered	 speech,	 ataxia,	 anosmia	 (loss	 of	 sense	 of	smell),	 unilateral	weakness	 and	numbness,	 vertigo	 (sensation	of	 spinning),	 headache,	and	diplopia	(double	vision).	A	trained	physician	in	a	clinical	setting	can	easily	identify	these	 symptoms	 and,	 based	 on	 the	 neurological	 deficiency	 identified,	 one	 can	 have	 a	good	idea	as	to	the	location	within	the	brain	where	damage	has	occurred.		After	 the	 initial	 assessment,	 a	 computed	 tomography	 (CT)	 scan	 can	 be	 performed	 to	better	assess	the	damage	and	to	visualize	the	stroke.	CT	can	be	conducted	either	with	or	without	contrast	dye.	The	most	frequently	used	form	is	non-contrast,	also	known	as	a	dry	 CT	 scan.	 This	 technique	 is	 suitable	 for	 assessment	 of	 fresh	 hemorrhage,	 but	 its	ability	to	detect	ischemic	stroke	is	poor.	However,	a	magnetic	resonance	imaging	(MRI)	scan	is	can	identify	both	old	and	recent	hemorrhages,	as	well	as	detect	brain	ischemia	[14].	Therefore,	an	MRI	scan	is	the	preferred	tool	to	assess	and	visualize	stroke.	
	
1.3 CLINICAL SYMPTOMATOLOGY AND FINDINGS IN CADASIL  
1.3.1 Migraine About	 20-40%	 of	 all	 CADASIL	 patients	 experience	 migraine	 with	 aura	 [2],	 the	 early	onset	of	which	has	been	associated	with	elevated	 levels	of	 serum	homocysteine	 [25].	Homocysteine	is	used	as	a	marker	of	an	elevated	risk	of	endothelial	damage,	leading	to	inflammation	and	arteriosclerotic	vascular	disease	[26].	These	attacks	can	last	from	20-30	minutes	 to	 a	 few	 hours.	 The	 severity	 of	 these	 attacks	 varies,	 with	 some	 patients	experiencing	 visual	 and/or	 sensory	 aura	 while	 others	 experience	 confusion,	 fever,	nausea	and,	in	the	most	severe	cases,	coma	[2].		Migraine	triggering	factors	in	CADASIL	are	the	same	as	those	of	a	classic	migraine.	The	frequency	 with	 which	 CADASIL	 patients	 experience	 migraines	 varies	 greatly	 and	 is	
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correlated	with	familial	lineage	[27].	CADASIL	diagnosis	is	challenging	and	misdiagnosis	often	occurs	due	to	the	fact	that	migraine	in	CADASIL	closely	mirrors	a	classic	migraine,	which	is	common	among	the	general	population.	In	fact,	about	50%	of	CADASIL	patients	suffering	 from	 migraine	 present	 with	 the	 same	 clinical	 features	 as	 classic	 migraine	episodes.	 As	 the	 disease	 progresses,	 additional	 symptoms	 begin	 to	 surface,	 including	subcortical	ischemic	attacks,	mood	disturbance,	and	cognitive	decline.	Diagnosis	is	more	commonly	made	when	the	patient	begins	to	suffer	from	ischemic	attacks.		
1.3.2 Diagnostic imaging  MRI	 and	 CT	 are	 the	 two	 most	 common	 imaging	 modalities	 used	 for	 diagnosis	 of	CADASIL.	Nonetheless,	MRI	 is	not	very	useful	at	an	early	stage	of	CADASIL,	as	 it	 lacks	enough	sensitivity	to	detect	brain	changes	preceding	the	early	clinical	symptoms.	There	are	 three	 types	of	brain	 lesions	observed	using	MRI	 and	CT	 in	CADASIL	patients:	 (1)	white	matter	hyper-intensities	(WMHI)	on	MRI	or	white	matter	hypo-densities	on	CT,	(2)	lacunar	infarcts	–	which	is	defined	as	occlusion	of	a	deep	penetrating	artery,	and	(3)	microbleeds.	The	 initial	 visible	 MRI	 changes	 are	 the	WMHIs,	 and	 these	 are	 typically	 found	 in	 the	anterior	part	of	the	temporal	lobe	and	also	in	the	periventricular	region	and	deep	white	matter.	The	most	affected	cerebral	areas	are	the	frontal,	parietal,	and	anterior	temporal	lobes,	while	the	occipital	lobe	is	less	affected	by	CADASIL	[28].	These	types	of	WMHI	are	not	only	observed	 in	CADASIL,	but	also	other	 small	 vessel	diseases.	Because	 they	are	associated	with	dementia,	 research	has	been	 increasingly	dedicated	 to	understanding	and	 predicting	 clinical	 outcomes	 based	 on	 their	 presence	 and	 prevalence.	 Reports	suggest	that	the	extent	of	WMHI	visible	on	MRI	(the	more	hyper-intensities	observed),	the	worse	the	clinical	outcome	and	severity	of	cognitive	disturbance	[29].		The	 most	 recent	 diagnostic	 imaging	 tool	 being	 used	 to	 study	 CADASIL	 is	 positron	emission	 tomography	 (PET).	 Glucose	 metabolism	 malfunction	 has	 been	 reported	 in	other	dementia	diseases	and	now	there	is	evidence	that	glucose	metabolism	is	altered	in	 CADASIL	 as	 well.	 Tuominen	 et.	 al.	 were	 able	 to	 show	 a	 correlation	 between	 the	reduced	 cerebral	 blood	 flow	 associated	 with	 CADASIL	 and	 glucose	 uptake.	 Although	these	 initial	 observations	were	 not	 statistically	 significant,	 additional	 studies	 suggest	glucose	uptake	is	altered	in	the	CADASIL	brain	[30,	31].									
1.4 CADASIL GENETICS 
1.4.1 NOTCH signaling  NOTCH	proteins	 are	 a	 family	 of	 type	 1	 transmembrane	 proteins	 involving	 in	NOTCH	signaling.	 In	 mammals,	 there	 are	 four	 NOTCH	 proteins,	 NOTCH1-4.	 In	 simple	 terms,	NOTCH	 receptors	 contain	 a	 NOTCH	 extracellular	 domain	 (NECD)	 and	 a	 NOTCH	intracellular	 domain	 (NICD)	 that	 are	 joined	 together	 by	 a	 single	 transmembrane	
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domain.	Both	NECD	and	NICD	interact	with	various	ligands.	Thus,	this	family	of	protein	receptors	can	be	 further	subdivided	based	on	their	 interacting	 ligands	(e.g.,	Delta-like	protein	family	and	Jagged	protein	family)	[32,	33].		These	ligand-mediated	transmembrane	receptors	are	relatively	simple	in	operation,	but	are	 key	 actors	 in	developmental	 processes	 and	diseases.	NOTCH	 signaling	 is	 a	 highly	conserved	 pathway	 and	 plays	 an	 active	 role	 in	 cell	 differentiation	 and	 apoptosis.	 All	members	of	this	family	of	proteins	are	similar	in	structure	where	the	NECD	contains	a	series	of	epidermal	growth	factor	repeats	(EFGRs).	NOTCH	signaling	 is	 initiated	when	NOTCH	 receptors	 on	 the	 cell	 surface	 engage	 ligands	 presented	 in	 trans	 on	 opposing	cells.		Jagged	ligands	contain	a	cysteine	rich	domain	(CRD)	while	Delta	ligands	lack	this	region,	which	 is	 upstream	 of	 EGFRs.	 These	 ligands	 have	 both	 Delta-Serrate-LAG3	 (DSL)	 and	amino	terminal	domain	(NT)	that	binds	to	EGF	repeats	11-12	for	activation	of	pathway.	NT	 also	 has	 a	 phospholipid	 binding	 ability,	 suggesting	 that	 it	 may	 help	 anchor	 and	stabilize	the	connection	between	the	sending	cell	and	receiving	cell.			A	 negative	 regulatory	 region	 exists	 on	 NECD,	 which	 consists	 of	 an	 interacting	heterodimeric	 portion	 of	 NOTCH	 and	 Lin127	 NOTCH	 repeats.	 This	 region	 is	 able	 to	shelter	 the	 cleavage	 site	 until	 a	 ligand	 has	 become	 bound	 to	 NECD.	 Upon	 activation,	ADAM	10	makes	the	first	cleavage	at	this	site.	The	first	cleavage	is	followed	by	a	second	cleavage,	which	is	accomplished	by	Υ-secretase.	Once	cleavage	has	occurred,	the	NICD	travels	to	the	nucleus	where	it	interacts	with	DNA	binding	protein	CBF-1	suppressor	of	Hairless-LAG1	 and	 mastermind,	 which	 function	 as	 co-activators	 thereby	 initiating	transcription	machinery	[32].		
	
 
Figure 2: NOTCH cellular signaling depicting NOTCH receptor and its cleavage sites. Upon receiving signal, NOTCH 
is cleaved and NECD is released while NICD is further cleaved before entering the nucleus.  	
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1.4.2 NOTCH3 Genetic	 risk	 factors	of	CADASIL	have	been	mapped	 to	 chromosome	19q13	and	many	mutations	 on	NOTCH3	 gene.	 This	 gene	 encodes	 for	 a	 single	 transmembrane	 protein,	NOTCH3,	which	 is	 composed	of	2,321	amino	acids,	 a	NECD	 that	has	34	EGFRs,	 and	a	NICD	 that	 is	 composed	 of	 seven	 ankyrin	 repeats	 [34].	 Each	 EGFR	 has	 six	 cysteine	residues.	The	mutation	pattern	in	this	region	is	essential	for	CADASIL	pathogenesis.		NOTCH3	forms	a	heterodimer	to	its	ligand	receptor	on	the	adjacent	cell,	which	contains	the	ligands	Jagged	and	Delta.	Upon	ligand	activation,	the	NOTCH3	receptor	undergoes	a	cleavage-dependent	activation	process.	NOTCH3,	like	other	NOTCH-family	proteins,	has	three	cleavage	sites:	S1,	S2,	and	S3.	S1	is	activated	during	maturation	while	the	S2	and	S3	cleavage	sites	are	ligand-binding	dependent.	S2	cleavage	releases	N3ECD,	leading	to	S3	 cleavage	 and	 the	 release	 of	N3ICD.	Upon	 cleavage,	N3ICD,	 similar	 to	 other	NICDs,	translocates	to	the	nucleus	where	it	activates	transcription	factors	CBF-1/RBPJκ.	
	
1.5 CADASIL PATHOLOGY  
1.5.1 Granular Osmiophilic Material (GOM) While	clinical	symptoms	and	mutations	vary	between	patients,	the	common	pathological	hallmark	 in	 all	 CADASIL	 patients	 is	 granular	 osmiophilic	 material	 (GOM).	 GOMs	 are	detected	by	a	staining	technique	known	as	Periodic	Acid	Schiff	(PAS).	GOMSs	are	defined	as	PAS	positive	material	that	measures	about	1-2	μm	in	size	 [5,	35].	Gray	and	white	matter	studies	 in	 the	CADASIL	 brain	 have	 shown	 that	 there	 are	 GOM	deposits	 associated	 with	 meningeal	 vessel	 and	perforating	 arteries.	 GOMs	 are	 exclusively	extracellular	 deposits	 and	 are	 associated	 with	NOTCH3	extracellular	domains	(N3ECDs)	[36].		GOM	 deposits	 have	 also	 been	 observed	 on	 arterial	smooth	muscle	cells	 in	 skin,	 retina,	muscle	 [37]	and	peripheral	nerve	[38]	and	have	functioned	as	a	golden	standard	 for	 diagnosis	 of	 CADASIL	 via	 electron	micrographic	imaging.	The	exact	composition	of	GOM	 is	highly	 controversial,	 with	 conflicting	 reports.	 The	 only	 component	 that	 has	 been	consistently	 verified	 by	 several	 groups	 is	 N3ECD	 [36,	 39].	 Recently,	 GOM	 depositions	were	 studied	 in	 postmortem	 human	 brain	 tissue	 with	 R1031C	 mutation.	 The	 tunica	media	 was	 targeted	 in	 brain	 arteries,	 resected	 by	 laser	 capture	 microdissection,	 and	analyzed	by	mass	spectrometry.	Proteomic	analysis	data	demonstrated	that	collagen	18	α1	and	clusterin	(also	known	as	Apol)	were	prevalent	in	CADASIL	samples	compared	to	control	samples,	and	presented	as	GOM	components	[40,	41].		
Figure 3: Electron micrograph 
picture of granular osmiophilic 
material (GOM) (photo: Docent 
Kjell Hultenby, KI).    
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Another	group	using	nano	liquid	chromatography–mass	spectrometry	(LC-MS/MS)	has	analyzed	 NOTCH3	 R90C	 transgenic	 mice	 and	 identified	 tissue	 inhibitor	 of	metalloproteinases	3	(TIMP3)	and	vitronectin	(VTN)	proteins	co-localized	with	N3ECD.	Logically,	 as	 GOM	 is	 composed	 of	 N3ECD	 (among	 other	 proteins),	 it	 has	 been	hypothesized	 that	 TIMP3	 and	 VTN	 should	 also	 be	 associated	 with	 GOM.	 Proteomic	analyses	of	vessels	prepared	 from	the	brains	of	CADASIL	patients	supports	 the	notion	that	 TIMPS	was	 enriched	 in	 GOM	 [42].	 Thus	 far,	 GOM	 composition	 cannot	 be	 clearly	delineated	and	whether	 its	composition	 is	static	or	 is	mutation/location	dependent	all	remains	undetermined.	
	
1.5.2 Pathology of vessels in CADASIL  CADASIL	 causes	 narrowing	 of	 the	 lumen	 of	 small	 arteries.	 The	 deep	 penetrating	 and	small	arterioles	are	most	commonly	affected;	however,	the	malfunction	of	blood	vessels	can	be	seen	in	medium-sized	blood	vessels	as	well	[43].	Pathological	findings	have	so	far	focused	on	the	brain	and	central	nervous	system	since	the	brain	is	the	most	vulnerable	organ	to	blood	flow	regulation,	but	CADASIL	pathology	has	been	reported	and	observed	in	 the	 small	vessels	of	other	organs	as	well,	 such	as	 the	kidney,	eyes,	 liver,	 and	heart	[44].		There	 is	 evidence	 that	 the	walls	 of	 the	 affected	 blood	 vessels	 become	 thickened	 and	fibrotic	 in	CADASIL	due	to	deposition	of	extra	cellular	matrix	(ECM)	proteins,	such	as	collagens	 [45],	 laminin	 [46],	 and	 fibronectin	[47].		Several	 pathological	 studies	 have	 provided	evidence	of	reduced	cerebral	blood	flow	(CBF)	in	 CADASIL	 [30,	 48].	 Morphological	 studies	corroborate	 such	 evidence	 with	 findings	 of	white	matter	arteriole	stenosis,	which	in	turn	explains	 the	 impaired	 endothelium-dependent	 vasodilation	 in	 resistance	 arteries	in	CADASIL	[49].	Another	study	by	Henshall	et	al	 showed	 that	 the	 blood	 vessel	 integrity	 in	 the	central	nervous	system	is	NOTCH3-dependent.	It	further	suggested	changes	in	NOTCH3	gene	 expression	 compromise	 vascular	 integrity	 [50].	 Therefore,	 the	 degeneration	 of	VSMCs	in	microvessels	and	the	impaired	vasodilation	of	vascular	cells	can	presumably	be	 affected	 by	 the	 changes	 of	 CBF	 in	 CADASIL.	 Recently,	 we	 published	 a	 paper	suggesting	that	TGFβ3	may	be	involved	in	ECM	protein	synthesis	and	thereby	causative	of	 one	 of	 the	 factors	 in	 fibrosis	 formation	 that	 disrupts	 the	 normal	 composition	 of	vasculature	in	CADASIL	[51]	The	 tunica	 adventitia	 is	 composed	 of	 collagen	 and,	 in	 the	 case	 of	 CADASIL,	 different	types	 of	 collagen	 have	 different	 expression	 patterns	 depending	 of	 the	 type	 of	 blood	vessel	 [52].	 In	 leptomeningeal	 arteries,	 collagen-I	 was	 loosely	 packed	 and	 became	
Figure 4: Light microscope picture of 
a vessel from a CADASIL patient 
showing fibrotic thickening. 
 10 
intensely	stained	compared	to	control	vessels.	This	phenotype	is	also	observed	in	small	penetrating	 arteries.	 However,	 capillaries	 have	 the	 same	 collagen-I	 pattern	 of	expression	and	phenotype	in	both	CADASIL	and	control	vessels.	Collagen-III	showed	a	similar	 staining	 pattern	 as	 collagen-I.	 The	main	 difference	was	 that	more	 transmural	staining	extended	into	the	tunica	media.	The	most	pronounced	difference	concerns	the	staining	 pattern	 of	 collagen-IV	 in	 CADASIL	 vessels.	 Leptomeningeal	 arteries	 showed	large	 collagen-IV	 deposits	 in	 the	 tunica	 media	 and	 tunica	 intima.	 While	 the	 same	phenotype	 was	 observed	 in	 small	 penetrating	 arteries,	 there	 were	 virtually	 no	differences	in	collagen	IV	staining	between	CADASIL	and	control	capillaries	[52].	These	types	of	fibrotic	thickening	cause	restricted	blood	flow,	which	renders	CADASIL	patients	more	prone	to	strokes.							
	
1.5.3 Endothelial Cells (ECs) As	previously	mentioned,	blood	vessels	consist	of	the	tunica	intima,	tunica	media,	and	
tunica	 adventitia	 layers.	While	 the	 tunica	 intima	 is	 not	 directly	 affected	 by	 CADASIL,	some	 reports	 show	 that	 ECs	 have	 an	 abnormal	 morphology.	 In	 a	 study	 of	 CADASIL	patient	 skin	 biopsy,	 Ruchoux	 et	 al	 have	 reported	 that	 ECs	 exhibited	 a	 “swollen”	appearance	that	disrupted	the	tight	junction	functionality	[53].	In	a	more	recent	study,	Ling	 et	 al	 have	 generated	 vascular	 endothelial	 cells	 from	 a	 patient	 with	 CADASIL	mutation	by	employing	induced	pluripotent	stem	cells	(iPSCs)	technique.	They	did	not	observe	 any	 abnormalities	 in	 these	 cells.	 However,	 it	 should	 be	 noted	 that	 only	 one	patient	was	involved	in	the	study	[54].		
1.5.4 Vascular Smooth Muscle Cells (VSMCs) Because	the	tunica	media	is	composed	almost	exclusively	of	VSMCs,	it	is	the	layer	most	affected	 by	 CADASIL.	 In	 CADASIL,	 the	 tunica	 media	 is	 significantly	 thinner	 when	compared	 to	a	control	vessel.	The	reason	 for	such	 thinning	 is	still	a	 subject	of	debate	with	no	conclusive	evidence	at	hand.	Some	reports	indicate	that	VSMCs	with	NOTCH3	mutation	have	a	higher	rate	of	apoptosis,	while	others	found	that	the	proliferation	rate	of	 VSMCs	 is	 lower	 than	 control	 and	 observed	 no	 signs	 of	 apoptosis	 [55,	 56].	Nevertheless,	 different	 mutations	 in	 the	NOTCH3	 gene	 may	 have	 varying	 affects	 the	VSMC	 apoptosis	 and	 proliferation	 rates.	 In	 addition,	 reports	 suggest	 that	 mutant	NOTCH3	may	result	in	faulty	VSMC	conditions	such	as	inappropriate	entry	into	mitosis,	irreversible	arrest	of	the	cell	cycle,	senescence,	degeneration,	or	loss	[57].	VSMCs	 are	 able	 to	 change	 phenotypes	 to	 adapt	 to	 their	 microenvironment	 via	inflammatory	factors,	cell-to-cell	interaction,	growth	factor,	and	other	avenues	[58,	59].	Upon	assault	and/or	injury	there	is	a	release	of	platelet-derived	growth	factor	(PDGF)	followed	by	down	regulation	of	α-smooth	muscle	actin	(α-SMA),	smooth	muscle	myosin	heavy	chain	 (SMMHC)	and	SM22-α	 [60].	 Interestingly,	PDGF	receptor	β	 is	 elevated	 in	
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CADASIL	 patient	 vessels	 and	 is	 associated	with	 pericytes	 [61].	 Nonetheless,	 NOTCH3	expression	is	not	under	direct	control	of	PDGF	[62].		Since	the	VSMC	layer	in	the	wall	of	CADASIL	vessels	is	thinner	than	normal,	it	has	been	hypothesized	that	NOTCH3	may	have	an	anti-apoptotic	function.	This	is	supported	by	a	study	using	rats	that	constitutively	express	N3ICD,	where	VSMCs	were	resistant	to	Fas	ligand	 induced	 apoptosis	 [63].	 The	 role	 of	 NOTCH	 and	 CBF-1/RBP-Jk	 has	 also	 been	investigated	and	it	was	found	that	their	cooperation	is	essential	in	cellular	homeostasis	and	 that	 their	 dysregulation	 leads	 to	 diseases	 such	 as	 T-lymphoblastic	 leukemia	 and	other	 forms	 of	 cancer	 [64].	 Whether	 the	 aforementioned	 anti-apoptotic	 function	 of	NOTCH3	is	CBF-1/RBP-Jk	dependent	is	still	highly	controversial	[65,	66].					
1.5.5 Pericytes  Pericytes	have	diverse	 functions	and	are	seen	mostly	 in	capillaries.	Their	 functions	 in	central	 nervous	 system	 capillaries	 are	 maintenance	 of	 the	 blood	 brain	 barrier,	gatekeeper	 for	 immune	 cell	 entry	 into	 the	 brain,	 and	 regulation	 of	 blood	 flow.	 These	cells	 induce	 constriction	 of	 capillaries	 after	 an	 ischemic	 event,	 which	 results	 in	 the	trapping	 of	 blood	 cells	 and	 prevention	 of	 microcirculatory	 reperfusion.	 Initially,	 this	function	was	believed	 to	be	 a	 task	of	 arterioles;	 however,	 it	was	 recently	 shown	 that	capillaries	are	more	efficient	at	regulating	blood	flow	[67].	Because	capillaries	are	also	affected	by	CADASIL,	Dziewulska	et	 al	have	 investigated	morphological	differences	 in	pericytes	 in	 CADASIL	 brain	 and	 skin	 biopsies.	 They	 have	 reported	 a	 loss/reduced	number	 of	 pericytes	 in	 capillary	 vessels	 as	 well	 as	 morphological	 changes,	 such	 as	shrunken	appearance	with	large	cytoplasmic	vacuoles	[68].		Subsequent	 studies	performed	 in	mice	have	 suggested	 that	NOTCH3	aggregation	 and	accumulation	 is	 the	 cause	 of	 pericyte	 pathology	 in	 CADASIL.	 The	 same	 group	 also	reported	a	loss	of	pericytes	that	is	correlated	to	age-related	accumulation	of	NOTCH3.	They	 confirmed	 the	 loss	 of	 pericytes	 in	 CADASIL	 and	 also	 linked	 pericyte	 loss	 to	astrocyte	end	 feed	detachment,	 leakage	of	plasma	protein,	and	reduced	expression	of	endothelial	 adhesion	 protein	 (which	 is	 required	 for	 formation	 of	 cellular	 tight	junctions).	The	most	important	finding	of	these	studies	is	perhaps	that	they	were	able	to	show	that	these	phenomena	occur	before	the	loss	of	VSMCs,	suggesting	that	the	disease	initiates	with	loss	of	pericytes	[69].											
1.5.6 NOTCH3 The	role	of	the	NOTCH3	gene	is	generally	unknown	and	its	expression	pattern	seems	to	be	 isolated	 to	 a	 few	 locations.	NOTCH3	 expression	has	 been	 reported	 in	VSMCs	 [70];	however,	 other	 protein	 atlases	 and	 other	 resources	 suggest	 that	 NOTCH3	 could	 be	expressed	 in	 locations	 other	 than	 VSMCs.	 Unlike	 a	NOTCH1	 deletion	 which	 is	 lethal,	
NOTCH3	 knock	 out	mice	 are	 fully	 viable	 and	 fertile	 [71].	 This	 suggests	 that	NOTCH3	protein	 is	 not	 important	 during	 the	 embryonic	 stage.	 Subsequent	 studies	 have,	
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however,	 illustrated	 that	NOTCH3	 knock	 out	 mice	 have	 blood	 vessel	 enlargement,	 a	thinner	 VSMC	 layer,	 and	 abnormally-shaped	 and	 -sized	 VSMCs.	 These	 mice	 exhibit	vessel	morphology	that	more	closely	resembles	a	venous,	as	opposed	to	arterial,	vessel	shape.	 Smoothlin,	 an	 arterial-specific	 marker	 that	 has	 been	 used	 to	 indicate	 the	maturation	 of	 VSMCs,	 was	markedly	 reduced	 in	NOTCH3	 knock-out	mice,	 suggesting	that	VSMC	differentiation	is	altered	in	these	mice	[72].		
	
1.5.7 Transforming Growth Factor Beta (TGFβ) and its role in CADASIL Many	 different	 factors	 have	 been	 identified	 as	 regulating	 VSMC	 growth	 and	proliferation.	One	of	 these	 factors	of	 importance	 for	us	 is	 transforming	growth	 factor	beta	 	 (TGFβ).	 	 TGFβ	 is	 a	 highly	 evolutionary	 conserved	 cytokine	 that	 is	 essential	 in	embryogenesis	 and	 homeostasis	 in	 adult	 tissue.	 In	 the	 TGFβ	 family,	 there	 are	 three	different	 TGFβ	 isoforms	 (TGFβ1,	 TGFβ2	 and	 TGFβ3),	 bone	 morphogenetic	 proteins	(BMP),	and	activins	[73,	74].	TGFβ	is	a	secretory	cytokine,	which	is	generated	in	dimeric	form	and	 then	cleaved	and	secreted	 [75].	TGFβ	 tightly	 regulates	VSMC	differentiation	via	TGFβRI	 and	TGFβRII.	Both	DeltaEF1	and	myocardin	were	 able	 to	 activate	 SM22α	actin	 transcription	 factor	 via	 TGFβ	 activation,	 suggesting	 that	 these	 factors	 are	important	for	differentiation	and/or	morphological	appearance	of	smooth	muscle	cells	[76,	77].	Growth	arrest	in	VMSCs	is	also	TGFβ	dependent	and	occurs	via	P38MAPK	and	Smad3.	It	 is	noteworthy	that	in	the	same	study,	they	also	showed	that	inducible	nitric	oxide	synthase	and	interleukin-6	were	both	down	regulated	[78].	TGFβ	also	plays	a	role	in	smooth	muscle	cell	migration,	which	is	regulated	by	cysteine-rich	protein	2	(CRP2).	CRP2	 is	 thought	 to	 be	 exclusively	 expressed	 in	VSMCs.	Over-expression	 of	 TFGβ	was	able	to	upregulate	CRP2	and,	hence,	inhibit	VSMC	migration	[79].		The	link	between	the	NOTCH3	and	TGFβ	has	been	investigated	in	myocardial	infarction	(MI)	 and	 cardiac	 pathology.	 In	 a	 study	 where	 a	 mouse	 model	 was	 used	 post-MI,	exogenous	 NOTCH3	 expression	 attenuated	 the	 fibrotic	 formation	 in	 and	 around	 the	area	of	assault	and	was	able	to	downregulate	TGFβ	expression.	These	data	suggest	that	NOTCH3	has	an	anti-fibrotic	function,	at	least	in	heart	[80].	TGFβ	and	its	role	in	fibrosis	have	been	documented	in	a	variety	of	diseases;	however,	its	role	in	fibrotic	stenosis	of	vessels	in	CADASIL	has	not	been	elucidated.		The	 notion	 that	 TGFβ	may	 be	 involved	 in	 SVD	 and	 CADASIL	 originate	 from	 a	 study	where	high	temperature	requirement	protein	A1	(HtrA1)	was	identified	as	an	activator	in	 the	TGFβ	pathway	 [81].	 Subsequent	 studies	 further	 illustrated	 the	 role	 of	 TGFβ	 in	CADASIL.	In	a	study	performed	by	Haffner	et	al,	 fibrillin-1	and	fibronectin	enrichment	were	not	co-localized	with	N3ECD,	while	 latent	TGFβ	binding	protein	1	(LTBP-1)	was	shown	to	co-localize	with	N3ECD.	The	conclusion	was	drawn	that	since	neither	fibrillin-1	 nor	 fibronectin	 is	 co-localized	with	 N3ECD,	 their	 enrichment	 is	most	 likely	 due	 to	fibrosis	 and	 LTBP-1,	 which	 does	 localize	 with	 N3ECD	 and	 is	 suggestive	 of	 N3ECD	aggregation	as	a	pathological	driver	[47].		
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Using	a	more	sophisticated	method	for	vessel	isolation	and	proteomic	analysis	by	mass	spectrometry,	previously	unknown	proteins	were	identified	in	CADASIL.	Among	them,	HtrA1	 was	 enriched	 in	 CADASIL	 samples	 and	 further	 investigation	 into	 this	 protein	showed	 an	 overlap	 between	 it	 and	 N3ECD.	 HtrA1	 substrates	 such	 as	 vitronectin,	clusterin,	and	elastin	were	all	enriched	in	the	CADASIL	brain,	while	gene	sequencing	of	HtrA1	failed	to	identify	any	mutations	that	would	inhibit	its	cleaving	ability	[82].	These	data	suggest	that	HrtA1	has	lost	its	function	in	CADASIL,	but	it	remains	to	be	explained	how	this	loss	of	function	has	occurred.							It	is	important	to	note	that	there	may	be	variation	between	the	experiments	and	results	as	 TGFβ	 expression	 and	 regulation	 is	 based	 on	 the	 local	 environment.	 Therefore,	 the	data	collected	 from	both	our	 lab	and	other	 labs	could	be	misguiding.	External	 factors	can	 affect	 TGFβ	 expression	 (and	 thus	 impact	 VSMC	 differentiation,	 viability,	 and	migration)	 such	 as	media	 composition,	 cell	 density,	 and	 temperature	 [83].	Moreover,	the	 regulation	 between	 ECs	 and	 VSMCs	 is	 tightly	 controlled.	 One	 of	 the	 regulatory	markers	for	ECs	is	TGFβ.	ECs	can	produce	latent	TGFβ	upon	interaction	with	SMCs	and	thereby	control	SMC	differentiation	and	function	[83].			
1.5.8 Inflammation in CADASIL  Inflammation	 is	 an	 important	 process	 in	 defending	 the	 body	 against	 invading	microorganisms,	as	well	as	recruiting	proper	cells	(e.g.,	immune	cells,	fibronectin,	etc.)	and	 cytokines	 (e.g.,	 IL-6,	 IL-12)	 to	 the	 injured	 site.	 However,	 this	 process	 itself	 can	become	pathological	in	cases	of	self-reactivity	and	enhanced	inflammatory	response	in	the	 brain.	 Ischemic	 stroke,	 which	 represents	 about	 80%	 of	 all	 strokes,	 has	 high	inflammatory	 elements	 [84,	 85].	 Upon	 assault,	 microglia	 and	 astrocytes	 become	activated	 and	 they,	 in	 turn,	 start	 the	 production	 of	 inflammatory	mediators	 [84,	 86].	There	 are,	 however,	 other	 cells	 such	 as	 ECs	 and	VSMCs	 that	 are	 able	 to	 produce	 the	same	cytokine.	The	role	of	the	cytokines	is	to	regulate	cell	proliferation,	activation,	and	differentiation.	There	are	several	types	of	cytokines	that	will	be	released	in	response	to	injury.	 However,	 for	 the	 purpose	 of	 this	 thesis	we	will	 focus	 on	 Interleukin-6	 (IL-6),	Interleukin-1-beta	(IL-1β),	Intercellular	Adhesion	Molecule	1	(ICAM-1),	and	TGFβ	[86].			IL-6	attracts	T-lymphocytes	 to	 the	 site	of	 injury	and	 is	produced	mainly	by	microglia	(69).	 IL-6	 levels	 peak	 about	 24	 hours	 post-stroke	 and	 its	 major	 role	 is	 pyrogenic	 in	nature	 [87].	 There	 are	 currently	 no	 studies	 performed	 on	 IL-6	 function	 in	 CADASIL	VSMCs;	 however,	 neuropathological	 examination	 of	 postmortem	 CADASIL	 brains	 has	suggested	that	there	is	elevated	levels	of	IL-6	in	association	with	ECs	[88].		IL-1β	 is	 initially	 produced	 by	 activated	microglia	 and,	 just	 like	 IL-6,	 has	 a	 pyrogenic	function.	Following	microglia	excretion	of	 IL1β,	 the	astrocyte	and	ECs	start	 their	own	production	 of	 this	 cytokine.	 Through	 the	 use	 a	 feedback	 loop,	 IL1β	 is	 able	 to	 further	activate	microglia	and	astrocytes,	leading	to	enhanced	IL1β	secretion.	It	can	also	cause	edema,	which	enhances	adhesion	of	leukocytes	to	the	endothelium	[86].					
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ICAM-1	is	expressed	on	several	cell	types,	including	ECs	and	VSMCs.	The	functional	role	of	 ICAM-1	 differs	 according	 to	 where	 it	 is	 expressed.	 On	 endothelial	 cells,	 its	 major	function	is	facilitation	of	diapedesis,	where	Lymphocyte	Function	Associated	Antigen	1	(LFA-1)	 on	 lymphocytes	 binds	 to	 ICAM	 and	 initiates	 transmigration	 [89].	 It	 is	conceivable	that	since	N3ECD	is	accumulated	extracellularly,	and	because	it	is	a	major	component	 of	 GOM,	 CADASIL	 may	 have	 an	 inflammatory	 element	 that	 develops	 in	response	to	these	pathological	hallmarks.					
1.5.9 Glucose metabolism and CADASIL PET	scan	results	from	several	papers	have	shown	a	reduction	in	glucose	uptake	and/or	metabolism	in	CADASIL	brains,	but	the	fundamental	molecular	mechanism	behind	such	findings	has	not	been	studied	[31].	There	are	other	disease	involving	dementia,	such	as	Alzheimer’s	 disease	 (AD),	 where	 glucose	 metabolism	 and	 uptake	 has	 been	 better	studied	in	mechanistic	fashion.						Glucose	is	transported	to	the	cell	via	two	different	transporters:	(1)	glucose	transporter	(GLUT),	 which	 is	 a	 facilitative	 sodium	 independent	 transporter,	 and	 (2)	 sodium	dependent	active	transporter	(SGLT).	Throughout	the	body	there	are	different	forms	of	GLUT	 transporters,	 with	 GLUT1	 being	 highly	 expressed	 in	 multiple	 types	 of	 cells	including,	 brain	 epithelial	 cells,	 glial	 cells,	 blood	 tissue	 barriers,	 eye	 cells,	 peripheral	nerve	 cells,	 placental	 cells.	 GLUT2	 is	more	 restricted,	 being	 found	 in	 astrocytes,	 liver	cells,	 islets	 cells,	 and	 epithelial	 cells	 of	 the	 small	 intestines	 and	 kidneys.	 GLUT3	expression	 can	 be	 observed	 in	 neurons,	 testicular	 cells,	 placental	 cells,	 and	 brain	endothelial	cells.	GLUT4	is	different	from	the	other	glucose	transporters	as	it	is	insulin-sensitive	and	 its	expression	 is	more	muscle-related.	 It	 is	expressed	 in	skeletal	muscle	cells,	smooth	muscle	cells,	and	myocardial	cells.	It	is	also	expressed	in	brown	and	white	adipose	neurons	in	the	cerebellum	and	hippocampus	[90].			Several	studies	have	concluded	that	decades	before	clinical	symptoms	of	AD	appears	in	patients,	 there	 is	 a	 reduction	 of	 glucose	 metabolism	 in	 the	 brain.	 There	 are	 several	working	hypotheses	that	attempt	to	explain	the	altered	glucose	metabolism	in	AD.	One	such	hypothesis	 is	 that	neurons	are	 less	active	due	to	mitochondrial	malfunction	and,	hence,	 there	 is	 a	 decreased	 need	 for	 sugar.	 A	 second	 hypothesis	 is	 that	 neurons	 are	more	 sensitive	 to	 damage	 and	 with	 death	 of	 these	 cells,	 the	 glucose	 requirement	 is	decreased	[91].				Nevertheless,	there	seems	to	be	a	correlation	between	glucose	uptake	and	metabolism	and	 neurodegenerative	 disorders.	 Whether	 the	 cerebral	 hypotrophy	 observed	 in	CADASIL	is	the	cause	or	effect	of	glucose	malabsorption	and	metabolism	remains	to	be	seen.										
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1.5.10 Autophagy There	are	generally	three	different	ways	endogenous	proteins	and	particles	can	become	degraded	 via	 lysosome.	 Degradation	 can	 be	 accomplished	 via	 chaperon-mediated	autophagy	 (CMA),	 micro-	 or	 macroautophagy	 [92].	 Macroautophagy	 is	 capable	 of	degrading	 aggregations,	 and	 is	 therefore	 a	 rather	 interesting	 candidate	 for	 the	degradation	of	aggregated	NOTCH3	[93].		The	 process	 of	 macroautophagy	 can	 be	 summarized	 into	 five	 steps	 [94].	 Once	macroautophagy	 is	 stimulated,	 a	 phagophore	 is	 formed,	 which	 is	 an	 isolation	 of	 the	membrane.	After	initiation,	the	phagophore	undergoes	elongation	and	proteins	targeted	for	degradation	 are	delivered	by	p62/SQSTM1.	p62/SQSTM1	 is	 capable	of	 binding	 to	LC3-II	 [95],	 an	 isoform	 of	microtubule-associated	 protein	 1A/1B-light	 chain	 3	 (LC3),	which	is	bound	to	the	phagophore,	allowing	for	the	incorporation	of	p62/SQSTM1	and	the	 misfolded	 protein	 into	 the	 phagophore.	 A	 completed	 phagophore	 is	 called	 an	autophagosome	and	it	fuses	with	lysosomes,	forming	an	autolysosome	that	is	capable	of	degradation.	 Deficits	 in	 the	 autophagic-lysosomal	 pathway	 result	 in	 protein	aggregation,	the	generation	of	toxic	protein	species,	and	accumulation	of	dysfunctional	organelles.	These	are	characteristics	of	many	neurodegenerative	disorders.		In	neuronal	development,	autophagy	has	been	observed	to	be	detrimental	as	deletion	of	ubiquitous	autophagy	genes	are	always	embryological	 lethal	 (as	detected	 in	knockout	mice),	 with	 the	 exact	 function	 in	 neurons	 still	 under	 investigation.	 Initially,	 it	 was	believed	 that	 the	 role	 of	 autophagy	 was	 to	 degrade	 proteins	 that	 were	 prone	 to	aggregation,	 such	 as	 those	 seen	 in	 Huntington	 disease,	 but	 later	 it	 was	 shown	 that	autophagy	is	also	important	in	homeostasis	and	cell	survival	[96].											Autophagy	has	shown	itself	to	be	important	in	other	neurodegenerative	diseases	such	as	 AD.	 One	 of	 the	 hallmarks	 of	 this	 disease	 is	 the	 amyloid-beta	 (Aβ)	 formation	 and	accumulation,	which	is	degraded	by	the	autophagy	process,	and	increasing	the	rate	of	this	 process	 decreases	 the	 levels	 of	 Aβ.	 However,	 autophagosomes	 contains	 both	amyloid	precursor	protein	(APP)	and	Presenilin-1,	which	cleaves	APP	to	form	Aβ.	This	raises	the	question	of	whether	Aβ	is	actually	formed	with	the	help	of	autophagosomes	[97].			Although	 the	 list	 of	 neurodegenerative	 diseases	where	 autophagy	 is	 involved	 is	 long,	very	 little	 is	 known	 about	 autophagy	 process	 in	 CADASIL.	 To	 date,	 there	 are	 three	reports	that	indicate	involvement	of	autophagy	in	CADASIL.	It	the	first	report,	Cognat	et	al	investigated	the	protein	kinase	R	(PKR),	a	pathway	that	is	involved	in	apoptosis	and	cellular	 stress	 and	 can	 potentially	 activate	 the	 autophagy	 process.	 Using	 four	postmortem	 CADASIL	 brain	 tissues	 and	 control	 brain	 tissue,	 they	 reported	 that	phosphoPKR	levels	where	higher	in	the	CADASIL	brain	compared	to	control.	However,	using	 LC3	 and	 ATG5	 markers	 as	 indications	 of	 autophagy,	 they	 were	 not	 able	 to	distinguish	 a	 different	 in	 levels	 between	 the	 control	 and	 CADASIL	 brain	 hence	 they	concluded	that	autophagy	is	not	a	player	in	CADASIL	pathology	[98].		
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While	Hase	et	al	studied	astrocytes,	they	realized	that	these	cells	in	CADASIL	have	larger	cell	 bodies	 and	 shortened	 or	 absent	 fibers	 compared	 to	 control	 brain.	 The	 CADASIL	brain	 also	 exhibited	 a	 reduced	 number	 of	 astrocytes,	 which	 instigated	 the	 study	 of	degradation	 in	 these	 cells.	 Using	 LC3	 and	 p62/SQSTM1	 as	 autophagy	 markers,	 the	group	investigated	the	role	of	autophagy	and	degradation	of	astrocytes	in	the	CADASIL	brain.	 Contrary	 to	 the	 report	 from	 Cognat	 et	 al,	 this	 group	 found	 elevated	 LC3	 and	p62/SQSTM1	 in	 astrocytes.	 They	 concluded	 that	 the	 degradation	machinery	 of	 these	cells	 is	 associated	 with	 the	 autophagy	 pathway	 [99].	 Given	 the	 findings	 from	 these	studies,	 it	 is	 still	 unclear	 if	 this	 autophagy	 plays	 a	 role	 in	 the	 pathological	 events	 of	CADASIL,	or	if	it	is	a	subsequent	reaction	to	NOTCH3	aggregation	and	accumulation.	Our	 group	 was	 the	 first	 group	 to	 present	 findings	 that	 the	 autophagy	 pathway	 is	disturbed	 in	 CADASIL	 VSMCs.	 We	 illustrated	 that	 lysosome-associated	 membrane	protein	2	(Lamp2)	a	 lysosomal	marker	was	elevated	 in	CADASIL	VSMCs	and	 this	was	correlated	 to	 an	 increase	 in	 the	 LC3/LC2	 ratio.	 These	 data	 suggest	 that	 there	 is	 an	increase	 in	 autophagosome	 formation	 and	 that	 the	 problem	 of	 NOTCH3	 aggregation	seems	 to	 be	 due	 to	 autophagosome	 inability	 to	 dock	 (fuse)	 with	 lysosomes	 when	aggregated	NOTCH3	should	become	degraded	[100].						
1.5.11 Animal models in CADASIL One	of	the	best	ways	to	conduct	research	is	by	creating	an	animal	model	that	mimic	the	human	disease.	In	the	case	of	CADASIL,	this	task	has	seen	strenuous	efforts	with	little	success	of	mimicking	CADASIL	disease	pathology.		Perhaps	the	most	robust	and	extreme	way	to	study	CADASIL	would	be	to	knock	out	the	
NOTCH3	 gene,	 creating	 a	 NOTCH3-/-	 mouse	 model.	 This	 model	 is	 viable	 and	 fertile,	meaning	 NOTCH3	 is	 neither	 essential	 for	 development	 nor	 for	 reproduction.	Interestingly,	this	mice	model	showed	none	of	the	classical	clinical	phenotypes	seen	in	CADASIL.	There	was	clearly	no	NOTCH3-/-	aggregation	or	N3ECD	accumulation	since	the	models	lacked	NOTCH3,	but	they	also	did	not	exhibit	any	white	matter	lesions,	lacunar	infarct,	GOM	formation	or	motor	deficiencies.	Upon	histological	analysis,	the	NOTCH3-/-	mouse	 did,	 however,	 display	 asymmetric	 dilation	 and	 contraction	 of	 arteries	 derived	from	 anterior	 part	 of	 the	 Circle	 of	 Willis.	 Additionally,	 the	 arteries	 of	 the	 brain	resembled	 veins	 with	 a	 smaller	 and	 thinner	 smooth	 muscle	 cell	 layer.	 Interestingly,	cerebral	arteries	 in	these	mice	were	unable	to	respond	well	 to	pressure	elevation	but	responded	 well	 to	 pharmacological	 agents	 that	 affected	 myogenic	 tone.	 These	 data	suggest	 that	 NOTCH3	 is	 important	 in	 autoregulation	 of	 cerebral	 blood	 flow	 and	maintenance	of	hyper/hypo-perfusion	[101].		Mouse	models	carrying	varied	CADASIL	mutations	have	repeatedly	been	used,	including	mice	carrying	either	the	C455R	or	R1031C	mutations	in	NOTCH3.		The	first	description	of	 C455R	 CADASIL	 mutation	 was	 discovered	 in	 a	 Colombian	 family	 in	 whom	 MRI	abnormalities	 were	 more	 extensive.	 The	 R1031C	 mutation	 was	 also	 described	 in	 a	Colombian	pedigree	[102].		
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C455R	 is	 located	 in	 the	 ligand-binding	domain	of	 the	NOTCH3	receptor	and	has	been	shown	to	be	involved	in	the	early	onset	of	stroke	[102].	On	the	other	hand,	R1031C	is	located	 outside	 of	 ligand-binding	 domain	 of	 NOTCH3.	 The	 mice	 carrying	 these	mutations	develop	GOM	and	other	age-dependent	phenotypes	that	resemble	the	human	condition	 [40].	 Using	 these	 animal	 models,	 many	 research	 groups	 have	 investigated	pathological	changes	in	CADASIL,	performed	principal	testing	of	experimental	drugs,	or	developed	new	therapeutic	treatments	for	CADASIL.	Other	attempts	 to	generate	mice	via	human	 full-length	NOTCH	with	R90C	and	C428S	mutations	yielded	conflicting	results.	Both	of	these	models	were	able	to	produce	GOM	and	N3ECD	accumulation,	but	were	void	of	white	matter	 lesions,	 lacunar	 infarcts,	and	motor	deficiencies.	One	caveat	to	generating	these	transgenic	mice	is	that	they	exhibit	85%	to	150%	expression	of	endogenous	murine	NOTCH3.				Moving	from	mice	to	rats,	CADASIL-like	models	carrying	either	full	length	NOTCH3	WT	or	NOTCH3	mutation	R169C	have	been	studied.	These	rat	models	demonstrated	closer	phenotypes	 to	 human	 CADASIL	 than	 current	 mice	 models,	 exhibiting	 both	 GOM	deposits	 and	 N3ECD	 accumulation.	 However,	 these	 rats	 expressed	 2-fold	 and	 4-fold	more	NOTCH3	protein	levels.	While	the	rat	that	expressed	a	4-fold	increase	of	NOTCH3	exhibited	white	matter	lesions,	the	rat	that	expressed	only	a	2-fold	increase	in	NOTCH3	expression	 lacked	 white	 matter	 lesions.	 However,	 both	 of	 these	 rats	 lacked	 lacunar	infarct	and	motor	deficits,	suggesting	protein	accumulation	on	its	own	does	not	cause	CADASIL	[43,	101].			
	
1.5.12 Current treatment  CADASIL	 symptoms	are	exacerbated	 if	 a	patient	has	other	 cardiovascular	 risk	 factors	and	 treatment	 plans	 are	 based	 on	 the	 current	 treatment	 options	 for	 cardiovascular	diseases.				Currently,	 there	 is	 no	 customized	 treatment	 for	 CADASIL	 and,	 therefore,	 the	 selected	treatment	regimen	is	entirely	pragmatic.	For	the	migraine,	one	should	be	very	hesitant	to	use	traditional	triptan	remedies	as	they	work	as	vasoconstrictors.	The	recommended	treatments	are	non-steroidal	anti-inflammatory	drugs	(NSAIDs)	for	pain	management,	prophylactic	β-blockers	to	regulate	heart	rate,	and	antiepileptic	drugs.		Prophylactic	 treatment	 of	 ischemic	 attacks	 is	 much	 more	 difficult.	 Caution	 has	 been	urged	 against	 the	 use	 anticoagulants,	 such	 as	 Coumadin,	 as	 these	 medications	 may	increase	the	risk	of	intracranial	hemorrhage.	Anti-platelet	drugs	are	used	in	these	cases	as	they	are	deemed	to	be	safer.	Anti-hypertensive	drugs	are	used	if	needed.	Statin	drugs,	commonly	prescribed	for	hypercholesterolemia,	are	currently	used	in	CADASIL	patients	to	 reduce	 HMG	 CoA	 in	 the	 cholesterol	 pathway.	 These	 drugs	 have	 been	 proven	 to	reduce	low-density	lipoprotein	(LDL)	levels;	however,	they	have	a	large	number	of	side	effects	[2].			
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There	are	currently	11	clinical	trials	either	underway	or	completed	with	CADASIL	as	a	main	or	side	target.	The	most	promising	treatment	being	tested	is	donepezil,	which	has	been	 used	 against	 dementia	 in	 AD.	 Donepezil	 is	 a	 reversible	 acetylcholinesterase	inhibitor.	In	a	clinical	study	testing	donepezil,	168	patients	with	CADASIL	were	selected	and	 86	were	 treated	with	 10mg/day	 donepezil	while	 82	 received	 placebo.	 18	weeks	post-study,	 there	 were	 no	 significant	 changes	 in	 the	 two	 groups,	 but	 there	 was	improved	 cognitive	 function	 in	 the	 CADASIL	 group	 [103].	 Other	 main	 targets	 in	CADASIL	drug	development	have	been	directed	toward	anti-platelet	drugs,	but	recently	there	has	been	a	shift	in	focus	to	NOTCH3	mutation	correction	[104].			 
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2 JOURNEY OF THIS THESIS When	we	embarked	on	this	PhD	project	four	years	ago,	not	much	was	known	about	the	molecular	 pathogenesis	 of	 CADASIL,	 and	 most	 of	 the	 information	 at	 hand	 was	 case	studies	 in	 clinical	 settings.	 The	 limited	 information	 about	 CADASIL	 was	 obtained	 by	transfecting	 human	 embryonic	 kidney	 (HEK)	 293	 cells	 with	 NOTCH3	 and	 NOTCH3	mutant	containing	plasmids.		Initially,	we	sought	 to	 transfect	human	aortic	vascular	smooth	muscle	cells	 (haVSMC)	with	 different	 NOTCH3	mutations	 that	we	 had	 constructed.	 The	 transfection	 became	more	daunting	and	time	consuming	than	we	expected.	In	our	arsenal	of	tools,	we	also	had	 immortalized	 umbilical,	 cerebral,	 and	 placental	 VSMCs	 taken	 from	 CADASIL	patients	with	the	C133R	mutation.	After	a	year	of	working	on	these	cells	and	trying	to	transfect	 haVSMC	 simultaneously,	 we	 decided	 to	 shift	 our	 focus	 towards	 cerebral	VSMCs	with	CADASIL	mutation.	We	realized	that	although	these	cells	were	derived	from	CADASIL	 patients	 with	 the	 same	mutation,	 they	 behaved	 differently	 under	 the	 same	conditions.	 Therefore,	 we	 concluded	 that	 to	 be	 able	 to	 get	 the	 most	 physiological	relevant	 data,	 we	 should	 continue	 our	 research	 with	 cerebral	 VSMCs	 obtained	 from	control	patients	and	CADASIL	patients.				Throughout	this	journey,	variations	between	the	different	VSMCs	became	apparent.	We	have	 learned	 that	VSMCs	 obtained	 from	 small	 vessels	 in	 the	 brain	 behave	differently	than	 VSMCs	 from	 other	 types	 of	 vessels	 (e.g.,	 aortic	 or	 placental)	 under	 the	 same	conditions.	This	observation	has	opened	a	new	area	for	further	research	–	to	study	the	differences	 between	 these	 cells	 and	 the	 cause	 of	 such	 differences.	 Because	 VSMCs	obtained	 from	 brain	 and	 placenta	 exist	 in	 different	 environments,	 it	 is	 possible	 that	their	functions	are	different.			
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3 AIMS 
 The	aims	of	this	PhD	thesis	and	work	were	to	establish	groundwork	for	clinical	events	in	VSMCs	containing	CADASIL	mutations.				
	
Aim	I	In	 the	 first	 paper,	 we	 studied	 the	 proliferation	 rate	 of	 CADASIL	 VSMCs	 with	 R133C	NOTCH3	mutation.	We	hypothesized	 that	TGFβ	 is	 involved	 in	 the	 lower	proliferation	rate	observed	in	CADASIL	VSMCs.					
Aim	II	The	 role	 of	 autophagy	was	 investigated	 in	 this	 study.	We	 tested	 the	 hypothesis	 that	impaired	 autophagy	 inhibited	 the	 proper	 degradation	 of	 aggregated	 NOTCH3	 in	CADASIL.				
Aim	III	In	 this	 study,	 the	 metabolic	 deficiencies	 in	 CADASIL	 VSMCs	 were	 examined.	 Our	hypothesis	was	that	glucose	transporters	are	down	regulated	in	CADASIL	VSMCs.			
Aim	IV	The	question	of	whether	inflammation	is	apparent	in	CADASIL	VSMCs	was	investigated	in	this	study.		  
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4 MATERIAL AND METHODS 
4.1 ETHICAL CONSIDERATIONS Studies	 involving	 human	 subjects	 carried	 out	 as	 part	 of	 this	 thesis	 were	 conducted	under	proper	ethical	permissions.	Ethical	permissions	were	obtained	from	the	Ethical	Board	 of	 the	 Hospital	 District	 of	 Varsinais-Suomi,	 the	 Ethical	 Committee	 of	 Turku	University	 Hospital,	 the	 National	 Authority	 for	 Medicolegal	 Affairs	 in	 Finland,	 the	Regional	Ethical	Review	Board	of	Stockholm,	the	local	research	ethics	committee	of	the	Newcastle	 Brain	 Tissue	 Resource	 (NBTR),	 or	 the	 Research	 Ethics	 Committee	 of	 the	South	 Huddinge	 University	 Hospital.	 Human	 subjects	 gave	 informed	 consent,	 when	required.		
 
4.2 ESTABLISHMENT OF CELL LINES AND CELL CULTURE Multiple	 vascular	 smooth	muscle	 cell	 (VSMC)	 lines	were	 used	 for	 experimentation	 in	Papers	 1-4	 of	 this	 these.	 All	 VSMC	 lines	 used	 for	 the	 experiments	 performed	 in	 this	thesis	originated	from	genetically	verified	CADASIL	patients	with	the	R133C	mutation	(VSMCCADASIL)	 and	 control	 subjects	 (VSMCWT).	 Genetic	 verification	 was	 done	 by	 gene	sequencing	 [105].	 VSMC	 lines	 were	 established	 from	 small	 blood	 vessels	 obtained	postpartum	 from	 pregnancies,	 in	 which	 either	 of	 the	 parents	 was	 diagnosed	 with	CADASIL	 (human	umbilical	 cord	 arterial	 VSMC,	 and	human	placental	VSMC),	 or	 from	post	 mortem	 subarachnoid	 branches	 of	 cerebral	 arteries	 (human	 cerebral	 arterial)	[105-107],	or	from	human	foreskin	fibroblasts	[108].		Umbilical,	 placental,	 and	 cerebral	 VSMCs	 and	 human	 foreskin	 fibroblasts	 [108]	were	cultured	 in	Dulbecco’s	modified	Eagle’s	medium	(DMEM)/Nutrient	Mixture	F-12	with	GlutaMAX,	supplemented	with	10%	heat-inactivated	fetal	bovine	serum	and	Penicillin-Streptomycin	 (100U/mL/	 -	 100µg/mL)	 at	 room	 temperature.	 Incubation	 of	 cell	 lines	was	performed	in	an	incubator	with	5%	CO2	at	37°C.	Cells	were	passaged	every	2	days	with	 a	 passage	 number	 of	 18-28.	 To	 partially	 immortalize	 the	 cell	 lines,	 they	 were	transduced	with	 a	 human	 papilloma	 virus	 construct	 p6/p7	 in	 early	 passage	 (p3–p5)	[105].	 Transduced	 cells	were	 selected	 by	 culturing	 the	 cells	 in	 the	 presence	 of	 G418	(400	μg/mL)	for	a	10-day	period.	
 
4.3 HUMAN SUBJECTS Where	human	subjects	have	been	used	for	this	thesis,	the	mean	age	of	CADASIL	subjects	were	 matched	 to	 the	 control	 subjects.	 Available	 case	 notes	 and	 radiological	 reports	indicated	 that	 CADASIL	 subjects	 showed	 extensive	 white	 matter	 changes	 consistent	with	 small	 vessel	 disease	 of	 the	 brain	 and	 met	 the	 minimum	 criteria	 for	 cognitive	impairment	 used	 in	 our	 post-stroke	 survivors	 study	 [109].	 CADASIL	 diagnosis	 was	conﬁrmed	 by	 the	 presence	 of	 NOTCH3	 gene	 mutations	 or	 the	 presence	 of	 GOM	 in	
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arteries	 within	 skin	 biopsies	 [110].	 None	 of	 the	 controls	 had	 neurological	 or	pathological	evidence	for	cerebrovascular	disease	or	neurodegenerative	disorder.		The	brain	tissues	from	CADASIL	subjects	(frontal	and	occipital	lobes)	and	aged-matched	controls	were	 from	 the	NBTR,	Newcastle	 University,	 Campus	 for	 Ageing	 and	 Vitality,	and	the	Swedish	Brain	Bank	(Stockholm,	KI).			
 
4.4 STAINING PROCEDURES 
4.4.1 Primary Staining VSMCs	were	 fixed	with	4%	paraformaldehyde	 (for	10	min	 at	 room	 temperature,	 and	permeabilized	using	0.3%	Triton	X-100	in	PBS	for	20	min.	at	room	temperature.	Cells	were	 then	washed	with	 PBS	 and	 blocked	 using	 either	 3%	normal	 goat	 serum	or	 1%	bovine	serum	albumin	(BSA)	diluted	in	PBS	for	30	min.	at	room	temperature.		
  
4.4.2 Double Staining VSMCs	were	washed,	 fixed,	 and	 incubated	 as	 described	 above	 (see	Primary	 Staining).	Cells	were	then	incubated	overnight	with	primary	antibodies;	N3ICD	and	KDEL,	as	an	endoplasmic	 reticulum	 (ER)	 marker	 at	 4°C.	 The	 following	 day,	 the	 samples	 were	washed	3	times	with	PBS	and	incubated	for	1h	with	the	secondary	antibodies.	
 
4.4.3 Triple Staining For	co-localization	of	NOTCH3	with	lysosomal	and	autophagy	markers,	before	and	after	treatment,	 triple	 immunostaining	was	also	performed.	The	cells	were	treated	with	CQ	for	24	h.	The	staining	procedure	was	done	as	described	above	(see	Other	Treatments).	The	 antibodies	 used	 for	 triple	 staining	were:	 anti-LC3,	 anti-Lamp2,	 and	 anti-NOTCH3	followed	by	incubation	with	secondary	antibodies.		
 
4.4.4 Immunofluorescence Staining Immunofluorescence	 staining	 was	 performed	 on	 5	 µm	 sections	 of	 formalin-fixed	paraffin-embedded	(FFPE)	frontal	cortex	of	post-mortem	brains.	The	sections	were	de-paraffinized	and	hydrated	through	xylene	and	graded	alcohol	series.	The	sections	were	autoclaved	with	antigen	retrieval	buffer	for	30	min	at	110°C.	When	room	temperature	was	 reached,	 sections	were	washed	with	water	 for	 5	min.	 and	 then	 in	 Tris-Buffered	Saline	(TBS) + 0.05	%	Tween®	20	(TBS-T).	The	sections	were	blocked	with	Background	Punisher	 for	10	min.	 at	 room	 temperature,	 followed	by	washing	 and	 incubation	with	primary	antibodies.	
  25 
After	 washing,	 sections	 were	 incubated	 (1h	 at	 RT)	 with	 appropriate	 secondary	antibodies.	Sections	were	again	washed	in	TBS-T	(3	×	10	min)	and	then	incubated	with	or	without	Sudan	Black	B,	for	5	min.	at	room	temperature	to	reduce	auto-fluorescence.	Sections	were	washed	 again	 in	 TBS-T	 and	mounted	with	 DAPI	 Vectashield	Hard	 Set.	Sections	from	controls	and	patients	were	also	incubated	without	primary	antibody	and	used	as	a	negative	control.		
 
4.5 OTHER TREATMENTS 
4.5.1 CFSE Labeling Carboxyfluorescein	 succinimidyl	 ester	 (CFSE)	 is	 a	 membrane-permeant	 fluorescein-based	dye	that	can	be	used	to	track	cell	division	due	to	the	progressive	halving	of	the	fluorescence	intensity	of	the	dye	in	cells	after	each	division.	After	cleavage	of	the	acetate	groups	 by	 the	 cell	 esterases,	 the	molecule	 becomes	 fluorescent	 and	 cell	 impermeant.	During	cell	division,	CFSE	is	partitioned	equally	among	the	daughter	cells.	That	property	is	 essential	 for	 visualization	 of	 cell	 proliferation	 where	 the	 intensity	 of	 CFSE	fluorescence	is	a	function	of	the	concentration	of	CFSE	and	the	duration	of	the	staining.	The	dye	has	been	used	to	monitor	the	proliferation	of	many	other	cell	types,	including	smooth	muscle	cells	[111].		CellTrace	 CFSE	 was	 used	 to	 enable	 tracking	 of	 VSMC	 proliferation.	 A	 5	 mM	 stock	solution	was	prepared	according	to	the	manufacturer’s	protocol	and	kept	at	-80°C	until	used.	 VSMCsCADASIL/WT	 were	 grown	 to	 90%	 confluence	 and	 harvested	 after	 washing	twice	 with	 PBS.	 The	 collected	 cells	 were	 centrifuged	 for	 5	 min	 at	 600	 ×	 g	 and	 the	supernatant	was	removed	 followed	by	re-suspension	of	 the	cells	 in	1	ml	pre-warmed	PBS.	One	population	of	cells	were	labelled	with	1	µM	CFSE	for	10	min	at	37°C.	The	cells	were	then	centrifuged	for	5	min	at	600	×	g	and	the	supernatant	was	replaced	with	1	ml	fresh	medium.	Labeled	cells	were	counted	by	Trypan-blue	using	a	hemocytometer,	and	equal	numbers	of	CFSE-labeled	cells	were	seeded	on	24-well	plates	and	incubated	for	either	3	or	7	days	at	37°C.		Unlabeled	cells	were	used	as	negative	controls.	For	the	loading	control	of	CFSE,	the	cells	were	labeled	with	CFSE	upon	running	through	the	flow	cytometer	in	parallel	with	other	samples.	 FL1	 was	 used	 to	 detect	 VSMCs	 loaded	 with	 CFSE.	 Flow	 cytometry	 was	performed	using	a	FACSCaliburTM	Cytometry.	Approximately,	5,000-20,000	events	were	collected	for	each	analysis.	For	direct	VSMC	culture,	the	CFSE-	labeled	VSMCsCADASIL/WT	were	 seeded	 in	 24-well	 plates	 and	 cultured	 with	 an	 equal	 number	 of	 the	 unloaded	VSMCsCADASIL/WT	 on	 the	 same	 side	 for	 3	 and	7	 days,	 harvested,	 and	prepared	 for	 flow	cytometry	as	described	above.	For	Paper	II,	VSMCs	were	treated	with	chloroquine	(CQ)	diluted	in	complete	medium	at	variant	 time	points.	CQ	 inhibits	 lysosome	protein	degradation	by	 increasing	 lysosome	pH,	which	 inhibits	 its	proteolytic	enzymes	and	causes	 the	accumulation	of	autophagic	
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vacuoles	[112,	113].	CQ	concentrations	were	based	on	values	presented	by	a	previous	report	[114].		
 
4.5.2 NBDG Glucose Uptake Assay Cells	 were	 incubated	 and	 grown	 in	 DMEM	 (see	 Establishment	 of	 Cell	 Lines	 and	 Cell	
Culture)	without	 the	 additional	 FBS	 and	 glucose	 for	 24	 h	 to	 a	monolayer	 confluence.	Later,	 the	 medium	 was	 removed	 and	 cells	 were	 washed	 3	 ×	 with	 PBS	 Krebs	 ringer	phosphate	buffer	with	50	mM	glucose	and	200	μM	2-NBDG	(2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose)	 was	 added	 to	 the	 cell	 layer.	 Cells	 were	incubated	with	and	without	50	mM	insulin	for	30	min.	The	cells	were	harvested	and	the	2-NBDG	uptake	was	measured	by	flow	cytometry	using	a	FACSCaliburTM	Cytometry.		
 
4.6 WESTERN IMMUNOBLOTTING Western	 blotting	 was	 used	 in	 Paper	 I,	 II,	 III	 and	 IV	 for	 protein	 measurement	 and	expression.		Total	protein	extracts	(10-25	μg)	were	mixed	with	2	×	SDS	sample	buffer,	boiled	for	5	min	and	loaded	onto	NuPAGE	4-12%	or	12%	Bis-Tris	using	NuPAGE	MES	or	MOPS	SDS	Running	Buffer.	Gels	were	blotted	with	the	wet	tank	transfer	system	using	Amersham	Protran	0.45	μm	Nitrocellulose	membrane	 and	 transfer	 buffer.	 The	membranes	were	blocked	using	5%	milk	in	TBS-T.	After	two	TBS-T	washing	steps,	the	membranes	were	incubated	ON	at	RT	or	4°C	with	the	primary	antibodies	diluted	in	5%	milk	and	0.2	%	sodium	azide.		The	 membranes	 were	 washed	 with	 TBS-T	 and	 incubated	 with	 specific	 secondary	antibodies,	 anti-rabbit	 and	 anti-mouse	 IgG	 conjugated	 with	 horseradish	 peroxidase	(HRP)	for	1	h,	at	RT.		For	Paper	III,	VSMCsCADASIL/WT	were	treated	as	described	above	prior	to	buffering,	except	that	 they	 were	 grown	 to	 80%	 confluence.	 Laemmli	 sample	 buffer	 was	 added	 to	 the	samples.	 2	 ×	 LDS	 sample	 buffer	 and	 used	 for	 SDS-PAGE	 and	 immunoblotting	 as	previously	described	[115].		
 
4.7 ANTIBODIES 
4.7.1 Transforming Growth Factor-beta (TGFβ) Antibody TGFβ	 Pan-specific	 neutralizing	 antibody	 was	 derived	 from	 porcine	 platelet-derived	TGFβ1	and	2,	which	detects	all	isoforms	of	TGFβ	receptors.	VSMCs	were	seeded	at	5	×	104	cells/mL	in	24	well	plates	and	cultured	overnight.	Later,	the	medium	was	changed	and	 cells	 were	 incubated	 in	 the	 presence	 or	 absence	 of	 12	 µg/ml	 TGFβ-neutralizing	antibody	for	24	h.		
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To	examine	the	effect	of	TGFβ	produced	by	placental	and	cerebral	VSMCsCADASIL/WT	on	endothelial	 cell	 proliferation	 rates,	 the	 placental	 and	 cerebral	 VSMCsCADASIL/WT	 and	endothelial	cells	were	co-cultured	in	a	non-contacting	co-culture	transwell	system	(Pore	size	0.4	μm).	Endothelial	 cells	were	plated	at	5	×104	cells/mL	 in	6-	or	24-well	plates.	Placental	and	cerebral	VSMCs	were	seeded	at	5	×	104	cells/mL	onto	the	membrane	of	transwell	cell	culture	 inserts	and	allowed	to	grow	overnight.	After	24	h,	 the	transwell	insert	membrane	containing	 the	VSMCs	was	placed	 into	plates	 containing	endothelial	cells.	VSMCs	were	treated	with	a	TGFβ-neutralizing	antibody	(12	μg/ml).		
 
4.7.2 Lamp2 Antibody To	 examine	 the	 co-localization	 of	 NOTCH3	 with	 lysosomes,	 in	 Paper	 II	 VSMCs	 were	stained	 with	 mouse	 Lamp2	 antibody	 to	 allow	 visualization	 the	 lysosomes.	 The	 cells	were	 then	 co-stained	with	N3ICD	 antibody	 to	 allow	 visualization	 of	 NOTCH3.	 VSMCs	were	exposed	to	CQ	and	incubated	for	different	incubation	times	(0,	1,	4,	and	24	h).	We	have	only	used	NOTCH3	antibodies	that	recognized	the	C	terminus	of	N3ICD	in	study	II.	
 
4.7.3 p62/SQSTM1 Antibody For	co-localization	of	NOTCH3	with	autophagy	marker,	VSMCs	were	stained	with	anti-p62/SQSTM1	antibody,	and	N3ICD.		
 
4.8 QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION (QRT-PCR) qRT-PCR	was	 used	 to	 investigate	 genes	 related	 to	 proliferation	 and	 the	 cell	 cycle	 in	placental	and	cerebral	VSMCs.	VSMCsCADASIL/WT	were	grown	overnight	in	a	6-well	plate	chamber	with	confluence	of	100.000	cells.	The	following	day,	the	cells	were	lysed	with	RIPA	 buffer	 and	 RNA	was	 isolated	 from	 VSMCsCADASIL/WT	 using	 RNeasy	 Mini	 kit.	 The	quality	of	isolated	RNA	was	determined	to	have	a	RIN-value	(RNA	Integrity	Number)	of	10.	 cDNA	 was	 synthesized	 using	 using	 Taqman	 gene	 expression	 master	 mix	 and	SuperScript	VILO	cDNA	Synthesis	kit	according	to	the	manufacturer's	protocol.	qRT-PCR	was	 performed	 using	 either	 (1)	 the	 TaqMan	Array	 targeting	 human	 cyclins	and	cell	cycle	regulation	or	(2)	costume	format	TaqMan	fast	plate.	The	TaqMan	Array	was	used	to	examine	whether	such	genes	are	disrupted	in	CADASIL.	The	panel	contains	probes	 targeting	 cyclins	 and	 cell	 cycle	 regulation	 associated	 genes,	 genes	 encoding	members	of	the	TGFβ	superfamily	of	ligands,	and	four	endogenous	control	genes.		The	 TaqMan	 Array	 Human	 TGFβ	 pathway	 plate	 was	 used	 for	 co-culture	 studies.	 All	TaqMan	 Probe	 qRT-PCR	 reactions	 were	 performed	 in	 triplicate	 in	 1×	 TaqMan	 Fast	Advanced	Master	Mix	with	30	ng	of	cDNA.	qRT-PCR	was	performed	on	a	7500	Fast	Real-Time	PCR	System.		
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4.9 IMAGING 
4.9.1 Immunoflourescent Imaging All	 immunofluorescent	 imaging	 was	 performed	 using	 a	 laser	 scanning	 confocal	microscope	 (LSM	 510	META,	 ZEISS,	 or	 core	 Facility	 Bionut	Microscopy),	 and	 images	were	 acquired	 using	 the	 same	 settings	 (laser	 intensity,	 detector	 gain	 and	 amplifier	offset).	 Also,	 the	 tissues	 fluorescence	 staining	 was	 recorded	 sequentially	 in	 separate	channels	with	Plan-Apochromate	20	×	(NA,	0.8),	40	×	(NA,	1.2)	oil	and	100	×	(NA,	1.45)	oil	 objectives.	 Image	 processing	was	 performed	with	 the	 included	 ZEN	 software.	 Cell	quantifications	 were	 performed	 with	 Neurolucida.	 Fluorescence	 intensity	 was	measured	with	the	ImageJ	1.383	software.		
 
4.9.2 Positron Emission Tomography (PET) and Magnetic Resonance (MRI) 
Imaging Ten	 CADASIL	 patients	 (4	 females,	 6	 males)	 with	 a	 confirmed	 R133C	 mutation	 on	
NOTCH3	were	 used	 as	 study	 subjects.	 The	 patients	 represented	 6	 families	 and	 had	 a	mean	age	of	33.7	±	5.2,	with	a	range	of	24	to	41	years.	Control	subjects	were	comprised	of	healthy	family	members	of	the	study	subjects	who	were	confirmed	to	be	lacking	the	R133C	mutation.	Controls	were	assessed	to	have	normal	T1w/T2w	MRIs	and	also	had	no	history	of	neurological	disorder	[30].		Neurological	 examinations	 and	 PET	 scans	 of	 study	 subjects	 were	 performed	 on	 the	same	 day.	 Cognitive	 status	 was	 assessed	 using	 the	 Mini-Mental	 State	 Examination	(MMSE)	[116].	PET	scanning	was	performed	using	a	GE	Advance	PET	scanner	in	the	2-dimensional	 scanning	 mode.	 The	 axial	 and	 transaxial	 spatial	 resolution	 of	 the	reconstructed	 images	was	 approximately	 5-mm	 full-width	 at	 half	maximum.	 2-[18F]-fluoro-2-deoxy-D-glucose	([18F]	FDG)	was	synthesized	as	described	earlier	[117,	118].	The	radiochemical	purity	exceeded	95%;	3.7	MBq/kg	was	injected	intravenously	and	a	dynamic	 scan	 for	 55	 minutes	 was	 performed.	 During	 the	 PET	 study,	 arterial	 blood	samples	were	drawn	from	the	radial	artery.	Within	one	month	of	the	examination	and	PET	scan,	MRI	was	performed.	Study	subjects	underwent	a	1.5	T	brain	MRI	and	3-dimensiona	T1	weighted	sequence	and	T2	weighed	sequence	were	acquired.	PET	and	MRI	images	were	matched	using	a	surface-fitting	method,	then	re-sliced	using	trilinear	 interpolation.	 Circular	 regions	 of	 interest	 (ROI)	 were	 drawn	 manually	 on	individual	MRI	images	on	the	frontal	and	occipital	white	matter	periventricularly,	on	the	frontal,	 temporal,	 and	 sensorimotor	 cortices,	 and	 on	 the	 hippocampus,	 putamen,	 and	cerebellum.	 The	ROIs	were	 then	 copied	 onto	 rCMRgluc	 images.	 The	 rCMRgluc	 values	were	calculated	in	mol/mL	per	minute	using	the	graphical	analysis	method	[30].	
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Statistical	 comparison	 of	 values	 between	 groups	 was	 measured	 by	 one-way	 ANOVA	followed	 by	 Bonferroni’s	 post-hoc	 test.	 Student	 t-test	 was	 used	 for	 two-group	comparisons.	p-values	< 0.05	were	considered	significant.	The	result	three	independent	biological	replicates	expressed	as	mean	±	S.E.M.		Un-adjusted	 bivariate	 comparisons	 of	 the	 PET	 measures	 between	 the	 CADASIL	 and	control	 groups	 were	 performed	 using	 independent	 samples	 t	 test.	 We	 then	 applied	generalized	 linear	 models	 (GLM)	 to	 adjust	 these	 comparisons	 for	 age	 and	 sex	 as	potential	 covariates	 in	 the	 models.	 Also,	 multivariate	 GLMs	 were	 used	 to	 explore	differences	in	PET	measures	between	males	and	females	and	how	they	interacted	with	the	effect	of	aging	on	the	cerebral	metabolic	rates	of	glucose	in	each	region	of	interest.	In	 each	 GLM,	 the	 rCMRgluc	 of	 each	 region	 was	 defined	 as	 the	 dependent	 variable,	whereas	age,	sex,	and	age-sex	interaction	were	the	independent	variables.	All	 univariate	 and	 multivariate	 analyses	 were	 performed	 using	 IBM	 SPSS	 Statistics	software	(version	23.0).	A	two-tailed	p-value	of	<	0.05	was	considered	as	the	threshold	for	statistically	significant	differences	or	associations	in	all	analyses.	
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5 RESULTS 
5.1 STUDY I The	most	apparent	pathological	marker	 in	CADASIL	 is	 the	 fibrotic	 thickening	of	small	vessels	in	the	white	matter	region	of	the	brain.	The	cause	for	this	stenosis	is	currently	under	 debate.	 It	 is	 clear	 that	 these	 vessels	 have	 at	 some	 point	 during	 the	 disease	progression	lost	their	VSMCs	or	that	VSMCs	have	been	replaced	by	fibrosis,	making	the	
tunica	 media	 layer	 thinner	 compared	 to	 a	 control	 blood	 vessels.	 There	 has	 been	discussion	that	VSMCs	in	CADASIL	are	more	prone	to	apoptosis	and,	hence,	the	thinning	of	 tunica	media	 occurs	 because	 of	 their	 higher	 apoptotic	 rate.	 The	 suggestion	 is	 that	once	 the	 VSMCs	 have	 under	 gone	 apoptosis,	 they	 are	 replaced	 by	 fibroblasts,	 which	results	 in	 the	manifestation	of	 fibrosis	 [63].	Our	group	has	previously	shown	that	 the	CADASIL	VSMCs	have	a	lower	proliferative	rate	compared	to	control	[56].			We	 further	 probed	 the	 cause	 of	 the	 low	 proliferation	 rate	 of	 CADASIL	 VSMCs	 by	focusing	on	cell	cycle	pathways	and	TGFβ3.	This	finding	was	in	accordance	with	other	groups	who	suggested	that	TGFβ	might	be	involved	in	CADASIL	disease	[47,	81].	TGFβ3	became	 the	 target	 as	 it	 has	 shown	 to	 be	 involved	 in	 fibrosis,	 VSMC	 function,	 and	remodeling	of	the	extracellular	matrix	[119,	120].		We	noticed	that	CADASIL	VSMC	cell	media	is	able	to	alter	the	proliferative	rate	of	other	cells	once	they	are	exposed	to	such	media.	Several	cell	 lines	such	as	EC,	control	VSMC,	 fibroblast	and	human	aortic	VSMC	were	affected	by	the	CADASIL	VSMC	growth	media	supernatant.	This	phenomenon	was	rescued	by	adding	neutralizing	anti	TGFβ3	antibody,	 suggesting	 that	CADASIL	VSMCs	secrete	 TGFβ3,	 which	 inhibits	 its	 own	 proliferative	 potential	 as	 well	 as	 that	 of	 its	neighboring	cells.	In	this	study,	we	improved	our	understanding	of	cell	proliferation	and	implicated	TGFβ	as	one	of	the	players	that	regulate	cell	proliferation	[51].		
5.2 STUDY II Studies	confirm	that	one	of	 the	first	events	 is	CADASIL	 is	 the	aggregation	of	NOTCH3.	This	aggregation	can	be	found	in	in	GOM	as	well	as	on	the	surface	of	VSMCs	[39,	121].	The	 accumulation	 of	 this	 protein	 and	 the	 lack	 of	 its	 degradation	 was	 the	 subject	 of	investigation	in	this	study.	Autophagy	is	one	of	the	key	degradation	pathways	in	protein	aggregation	and	we	hypothesized	that	this	pathway	is	affected	in	CADASIL.	To	further	corroborate	 other	 studies,	 we	 performed	 a	 Thioflavin-S	 staining	 to	 illustrate	 protein	accumulation.	This	staining	is	used	widely	as	a	screening	tool	for	protein	aggregation.		Next,	we	measured	LC3	expression	in	CADASIL	VSMCs	compared	to	control	VSMCs.	LC3,	an	autophagosome	marker,	was	significantly	higher	in	CADASIL	VSMCs,	suggesting	that	there	is	a	disruption	in	the	autophagy	pathway.	This	finding	led	us	to	analyze	the	fusion	of	 the	 autophagosome	 and	 lysosome.	 Upon	 treatment	 with	 chloroquine,	 a	 lysosomal	inhibitor,	the	degree	of	LC3	levels	increased	in	control	VSMCs	while	it	remained	steady	in	 CADASIL	 VSMCs.	 These	 results	 suggested	 to	 us	 that	 the	 autophagy	 pathway	 is	important	in	the	clearance	of	aggregated	NOTCH3	[100].		
  31 
 
5.3 STUDY III  Metabolic	investigation	in	CADASIL	has	been	limited	to	PET	images	with	the	consensus	being	 that	 glucose	uptake	 is	 lower	 in	 the	CADASIL	brain.	 Some	of	 these	 studies	have	attributed	lower	glucose	uptake	to	impaired	cerebral	blood	flow	[30,	122].	Using	CVD	as	inspiration,	we	revisited	some	of	the	PET	scan	data	and,	in	line	with	CVD,	observed	that	age	and	sex	factors	were	associated	with	CADASIL	disease	progression.		Next,	we	sought	to	investigate	the	glucose	uptake	on	cellular	level	in	CADASIL	VSMCs.	Initial	 experiments	 in	 glucose	 uptake	 gene	 expression	 suggested	 that	 several	 glucose	transporters	 had	 a	 lower	 expression	 level	 in	 CADASIL	 VSMCs	 compared	 to	 control	VSMCs.	 We	 further	 investigated	 the	 functional	 effect	 of	 lower	 glucose	 uptake	expression.	As	a	baseline,	CADASIL	VSMCs	had	lower	glucose	uptake	relative	to	control	VSMCs.	 To	 increase	 this	 uptake,	we	 used	 insulin	 to	 activate	 glucose	 uptake	 of	 Glut4.	Although	 using	 insulin	 did	 increase	 glucose	 uptake	 in	 CADASIL	 VSMCs,	 it	 did	 not	completely	increase	the	glucose	uptake	to	control	level.	This	is	most	likely	due	to	other	glucose	transporters,	such	as	Glut2	and	3,	which	were	also	down	regulated	in	CADASIL	VSMCs	being	insulin-independent.		Here,	we	have	demonstrated	that	although	cerebral	blood	flow	is	one	reason	for	lower	glucose	uptake	in	the	CADASIL	brain,	lower	glucose	uptake	is	also	observed	in	VSMCs.	The	question	 that	 remains	 is	whether	 an	 increase	 glucose	uptake	 in	CADASIL	VSMCs	would	 make	 these	 cells	 more	 viable	 and,	 in	 turn,	 reduce	 the	 number	 of	 VSMCs	 in	vessels,	as	it	is	a	reported	in	CADASIL.	
 
5.4 STUDY IV  In	many	neurodegenerative	diseases,	 inflammation	plays	an	active	role.	However,	 the	role	 of	 inflammation	 and	 its	 activity	 has	 so	 far	 not	 been	described	 or	 investigated	 in	CADASIL.	 The	 VSMCs	 containing	 CADASIL	 mutation	 behave	 differently	 and	 their	survival	 condition	 and	 proliferation	 differed	 compared	 to	 control	 VSMCs.	 Having	 the	data	 from	paper	 I,	 II,	 and	 III,	 and	 considering	 that	 inflammatory	 response	 is	 a	major	contributing	factor	to	many	vascular	events,	we	sought	to	investigate	whether	mutated	CADASIL	VSMCs	are	able	to	invoke	an	immune	response.		We	initiated	the	study	by	reviewing	different	expression	levels	of	genes	that	has	been	shown	 to	 be	 involved	 in	 inflammatory	 responses.	 The	 first	 observation	 by	 qRT-PCR	technique	 showed	 high	 gene	 expression	 of	 inflammatory	 genes	 in	 CADASIL	 VSMCs	compared	 to	 control.	 Among	 these	 genes,	 we	 focused	 on	 IL-6	 and	 ICAM-1.	 Using	western	blot	analysis,	we	could	confirm	that	the	observed	high	level	of	IL-6	and	ICAM-1	gene	expressions	was	similar	to	the	protein	level.	When	we	co-cultured	CADASIL	VSMCs	with	an	endothelial	cell	line,	we	observed	that	mutated	VSMCs	affected	ECs	by	inducing	a	higher	IL-12R	expression	suggesting	that	cytokines	secreted	by	CADASIL	VSMCs	have	an	 effect	 on	 the	 neighboring	 cells.	 Preliminary	 results	 of	 stained	 post	 mortem	 brain	
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tissues	from	CADASIL	patients	demonstrated	highly	activated	microglial	cells.	Of	note,	there	were	nearly	no	indications	of	microglial	positivity	in	control	tissues.	Preliminary	data	from	immunohistochemical	staining	of	activated	microglial	cells	in	CADASIL	brain	tissues	suggest	more	general	 inflammatory	responses	than	the	local	one	generated	by	VSMCs.	Even	though	this	study	is	in	its	infancy,	it	is	providing	significant	information	of	possible	 inflammatory	 effect	 involved	 in	 CADASIL	 pathology.	 Knowing	 that	inflammation	 may	 affect	 the	 VSMCs	 in	 the	 brain,	 and	 there	 is	 a	 possibility	 of	 other	inflammatory	sources	in	the	CADASIL	brain,	it	can	provide	a	novel	disease	targeting	for	dampening	this	inflammatory	process	thereby	slowing	down	the	disease	progression.	
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6 DISCUSSION AND WAY FORWARD 
 Since	 the	 discovery	 that	 a	mutation	 on	 the	NOTCH3	 gene	 causes	 CADASIL	 in	 1996,	great	strides	have	been	made	in	CADASIL	research	but	much	more	work	needs	to	be	done	to	fully	understand	the	disease	and	its	progression.	The	initial	work	on	CADASIL	was	performed	on	 cells	 that	 are	easily	 transfected	 (e.g.,	HEK293	cells).	 	These	early	studies	 shed	 light	 on	 issues	 such	 as	 signal	 transduction,	 protein	 aggregation,	 and	cellular	response.	They	also	 laid	 the	groundwork	 for	more	advance	and	complicated	animal	models	as	well	as	more	in-depth	studies	of	CADASIL.	There	are	many	studies	characterizing	new	CADASIL	mutations,	in	addition	to	reports	that	constantly	identify	new	 families	 with	 CADASIL,	 co-morbidity	 with	 other	 diseases,	 and	 involvement	 of	organs	other	than	the	brain.			ECG	studies	have	 indicated	 that	CADASIL	patients	also	have	 cardiac	pathology,	with	25%	 of	 CADASIL	 patients	 having	 an	 abnormal	 Q-wave	 or	 recorded	 MI	 [123,	 124].	While	it	is	hard	to	concretely	claim	that	CADASIL	affects	the	microcirculatory	system	of	 the	 heart,	 it	 is	 conceivable	 that	 CADASIL	 affects	 more	 than	 merely	 the	 brain	microcirculatory	system.	Other	studies	have	implicated	the	kidneys	and	ocular	system	as	potential	organs	that	can	be	affected.	In	the	kidneys,	evidence	suggests	that	there	is	NOTCH3	 aggregation/accumulation	 and	 GOM	 in	 the	 perivascular	 space,	 as	 well	 as	stenosis	of	renal	arteries.	However,	there	is	currently	no	evidence	that	kidney	function	has	been	affected	[125,	126].		Large-scale	studies	are	needed	to	conclusively	rule	out	CADASIL	as	having	no	effect	on	kidney	function.			CADASIL	appears	to	affect	the	ocular	vascular	system	as	well.	In	a	recent	study,	Nelis	et	al	used	optical	coherence	tomography	angiography	to	show	that	CADASIL	patients	have	a	lower	vessel	density	of	the	deep	retinal	plexus	[127].		Previously,	others	have	demonstrated	stenosis	of	the	central	retinal	artery	and	its	branches,	GOM	deposition	perivascularly,	 and	 nerve	 fiber	 loss.	 However,	 to	 date,	 there	 are	 no	 reports	 that	CADASIL	causes	loss	of	vision	[128,	129].						Considering	 that	many	organs	 are	 affected	by	CADASIL,	 there	 is	 a	 consensus	within	the	 CADASIL	 field	 indicating	 that	 aggregation	 of	 NOTCH3	 is	 the	 cause	 for	 major	pathology	 seen	 in	 this	 disease.	 But	 no	 direct	 link	 has	 been	 made	 between	 the	angiopathy	observed	in	CADASIL	and	NOTCH3	aggregation	and	accumulation.	Several	groups	have	tried	to	study	the	effect	of	NOTCH3	aggregation	on	vessels	by	inducing	an	immune	 response	 to	 clear	 out	 the	 aggregates,	 or	 by	 using	 antibodies	 to	 activate	NOTCH3	 signaling.	 Activation	 of	 NOTCH	 pathway	 is	 based	 on	 its	 cleavage.	 For	 this	reason,	Li	et	al	designed	a	study	where	they	were	able	to	activate	and	inhibit	NOTCH3	signaling	in	HEK293T	cells	with	the	help	of	antibodies	generated	in	their	group.	Their	work	was	 focused	 on	NOTCH3	 signaling	 due	 to	 its	 role	 in	 cancer	 development	 and	progression,	especially	in	non-small	cell	lung	cancer	and	ovarian	cancer	[130].			
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Due	 to	 the	mural	 cell	 (VSMCs	 and	 pericytes)	 loss	 observed	 in	 CADASIL,	 later	work	used	 these	 antibodies	 to	 implicate	 NOTCH3	 signaling	 in	 CADASIL	 disease.	 A	mouse	model	 was	 generated	 with	 a	 C455R	mutation	 since	 this	 mutation	 is	 on	 the	 ligand-binding	domain	of	NOTCH3	and	 is	 thought	 to	disrupt	 the	signaling	greatly.	 It	 is	also	evident	 that	 human	 patients	 with	 this	 mutation	 have	 a	 more	 aggressive	 clinical	manifestation	 of	 CADASIL	 [102].	 Additionally,	 knock	 out	 mice	 lacking	 the	NOTCH3	gene	were	generated	for	comparison	purposes.	Although	the	knock	out	mice	did	not	show	any	signs	of	stroke	or	changes	in	the	white	matter,	they	did	exhibit	loss	of	mural	cells.	The	C455R	mice	presented	GOM	formation	but,	like	the	knock	out	mice,	they	also	did	not	exhibit	stroke	or	white	matter	changes	in	the	brain.	Adding	agonist	NOTCH3	antibody	to	C455R	mice	rescued	signaling	disruption	while	inhibiting	the	loss	of	mural	cells.	 These	 data	 suggest	 that,	 in	 CADASIL,	 the	 signaling	 pathway	 disruption	 due	 to	mutation	 of	 NOTCH3	 is	 an	 important	 pathological	 driver	 and	 could	 be	 rescued	 via	agonist	 NOTCH3	 antibody	 [131].	 	 This	 research	 raised	 the	 question	 of	 whether	NOTCH3	aggregation	is	the	causative	factor	in	mural	cell	loss	or	if	it	is	a	byproduct	of	the	disease.	It	also	suggested	that	a	loss	of	signal	transduction	in	mural	cells	could	be	the	underlying	cause	for	the	loss	of	such	cells.			To	 further	 investigate	 the	possibility	 that	NOTCH3	aggregation	 is	pathology	causing,	Ghezali	 et	 al	 studied	 whether	 passive	 immunization	 with	 N3ECD	 would	 improve	CADASIL	 outcomes.	 	 Using	 NOTCH3	 R169C	 mouse	 model,	 this	 study	 confirmed	previous	 findings	 that	N3ECD	accumulates	over	 time	and	 that	 these	animals	 exhibit	cerebrovascular	 dysfunction	 with	 white	 matter	 lesions.	 Using	 an	 antibody	 directed	towards	the	ECD	of	NOTCH3	(5E1),	they	injected	the	mice	once	a	week	for	20	weeks.	They	further	 investigated	GOM	and	N3ECD	deposition	perivascularly,	and	concluded	that	 there	was	 no	 significant	 reduction	 in	 deposition	 between	 immunized	mice	 and	control	mice.	The	 recruitment	of	microglia	 cells	 around	 the	vessel	was	not	different	between	 the	E51	 treated	mice	and	control	mice,	and	 immunization	had	no	effect	on	white	matter	lesions	between	these	groups	[132].	The	major	finding	of	this	research	was	that	 there	 is	 improvement	to	myogenic	 tone	 in	the	5E1	treated	NOTCH3	R169C	mouse	model,	 suggesting	 that	 improving	myogenic	 tone	will	 not	 alleviate	 the	white	matter	lesions	observed	in	CADASIL.			In	 our	 initial	work,	we	 implicated	 TGFβ	 as	 one	 of	 the	 players	 involved	 in	 CADASIL	pathology.	We	hypothesized	that	TGFβ	secretion	by	VSMCs	induces	fibrosis	as	well	as	degeneration	of	VSMCs	in	the	vessel.	Initiating	treatment	in	our	cells	with	neutralizing	TGFβ	antibody	restored	the	proliferative	rate	of	CADASIL	VSMCs	compared	to	control	VSMCs,	raising	the	 interest	of	neutralizing	TGFβ	antibody	as	a	therapeutic	means.	 In	this	study,	we	used	a	cell	line	that	was	established	from	one	human	with	one	CADASIL	mutation,	namely	R133C.	For	that	reason,	the	observed	effect	of	NOTCH3	mutation	on	TGFβ	could	potentially	be	a	 cell	 line-specific	or	mutation-specific	 effect.	 It	would	be	interesting	to	generate	more	cell	lines	with	different	mutations	to	test	the	effect	those	mutations	 have	 on	 TGFβ.	 Our	 study	 focused	 on	 TGFβ3,	 a	 subtype	 of	 TGFβ	 that	 is	involved	 in	 fibrosis.	 This	 could	 be	 to	 our	 advantage	 as	 the	 neutralizing	 antibody	specific	 for	 TGFβ3	 could	 be	 used	 to	 inhibit	 fibrosis	 in	 CADASIL	 and	 increase	 VSMC	
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proliferative	 rate.	 To	 test	 the	 beneficial	 effect	 of	 neutralizing	 antibody	 specific	 for	TGFβ3,	 we	 would	 need	 a	 CADASIL	 animal	 model	 where	 we	 could	measure	 fibrotic	thinking	of	brain	blood	vessels	 and	disease	progression.	The	major	 caveat	with	 this	therapy	 would	 be	 the	 off	 target	 affects	 this	 antibody	 would	 have	 and	 this	 therapy	could	potentially	disrupt	the	normal	philological	function	of	TGFβ	systemically.				In	our	next	project,	we	demonstrated	that	autophagy	was	involved	in	CADASIL	disease	progression	and	accumulation	on	NOTCH3	aggregates.	We	showed	that	 the	problem	arises	when	 the	 lysosome	 is	 unable	 to	 dock	 properly	with	 the	 autophagosome.	We	used	 cerebral	 VSMCs	 with	 R133C	 mutation	 in	NOTCH3	 gene.	 To	 follow	 up	 on	 this	study,	we	would	 need	 to	 establish	 several	 different	 cerebral	 VSMC	 lines	 containing	other	 CADASIL	 mutations.	 CADASIL	 patients	 with	 C445R	 mutation,	 as	 described	previously,	have	severe	symptoms	of	CADASIL	with	early	ischemic	attacks.	It	would	be	interesting	 to	 investigate	 the	 accumulation	 and	 aggregation	 of	 NOTCH3	 in	 VSMCs	containing	C445R	NOTCH3	mutation.	Based	on	our	 findings,	we	believe	 that	VSMCs	containing	 C445R	 NOTCH3	 mutation	 should	 exhibit	 more	 aggregation	 and	accumulation	 and	 far	 more	 autophagosomes	 compared	 to	 our	 current	 cell	 model.		Currently,	 the	 issue	 of	 NOTCH3	 aggregation	 and	 accumulation	 and	 its	 pathological	role	 in	 CADASIL	 has	 not	 been	 fully	 described.	 We	 believe	 that	 if	 we	 could	 show	correlation	 between	 the	 different	 CADASIL	 mutations	 and	 an	 increase	 in	autophagosomes	 and	 disease	 progression,	 we	 could	 potentially	 demonstrate	 that	aggregation	of	NOTCH3	is	the	pathological	driver	in	CADASIL.			Next,	 we	 investigated	 glucose	 uptake	 in	 CADASIL	 VSMCs	 and	 compared	 it	 control	VMSCs.	We	noticed	that	glucose	transporters	are	down	regulated	in	CADASIL	VSMCs	relative	to	control	VSMCs	and	that	this	down	regulation	had	a	functional	effect	in	the	sense	that	CADASIL	VSMCs	were	not	able	to	take	up	glucose	as	well	as	control	VSMCs.	One	 transporter	 that	 was	 down	 regulated	 was	 GLUT4,	 which	 is	 the	 only	 insulin-dependent	transporter	in	our	data	set.	Experimental	set	up	was	performed	by	adding	insulin	 to	 the	media	and	measuring	 the	 total	glucose	uptake	 in	CADASIL	VSMCs	and	control	VSMCs.	 Insulin	 increased	glucose	uptake	 to	some	extent,	which	supports	 the	notion	 that	 VSMCs	 utilize	 more	 than	 GLUT4	 for	 their	 glucose	 uptake.	 It	 should	 be	noted	that	the	insulin-independent	transporters	were	also	down	regulated	but	could	not	be	rescued	with	insulin.			Staining	for	glucose	transporters	in	post	mortem	brain	tissues	from	CADASIL	patients	confirmed	our	cell	model	and	allowed	visualization	of	the	down	regulation	of	glucose	transporters	in	CADASIL	cerebral	vessels	compared	to	control	tissues.	An	interesting	observation	 was	 that	 larger	 cerebral	 vessels	 did	 not	 exhibit	 low	 levels	 of	 glucose	transporters	to	the	same	extent	as	smaller	vessels.	Some	CADASIL	mutations	produce	symptom	manifestation	and	 signs	of	 the	disease	earlier	 than	others,	 suggesting	 that	those	mutations	are	more	harmful.		As	a	follow-up	study,	it	would	be	interesting	to	use	brain	 tissues	with	different	CADASIL	mutations	and	observe	glucose	 transporters	 in	those	 samples.	 One	 would	 suspect	 that	 the	 more	 harmful	 the	 mutation	 is,	 the	 less	glucose	transporters	will	be	observed	on	VSMCs	in	post	mortem	tissues.	Also,	it	would	
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be	 interesting	 to	 find	 subject	 with	 CADASIL	 and	 diabetes	 and	measure	 the	 glucose	uptake	 in	 the	 brain	 via	 PET	 and,	 if	 possible,	 obtain	 brain	 tissues	 to	 measure	 the	abundance	of	glucose	transporters	 in	both	the	brain	tissue	and	cerebral	VSMCs.	 It	 is	possible	 that	 comorbidity	 of	 diabetes	with	 CADASIL	would	 exacerbate	 the	 CADASIL	disease	progression.							In	a	subsequent	study,	we	focused	on	the	inflammatory	role	in	CADASIL	by	measuring	pro-inflammatory	markers	in	CADASIL	VSMCs.	We	hypothesized	that,	since	CADASIL	VSMCs	are	 less	resistant	 to	stress	and	are	generally	weaker	 than	their	counterparts,	they	may	 produce	 and	 secret	 inflammatory	 cytokines	 as	 a	 “cry	 for	 help”	 to	 recruit	other	cells	or	molecules.		The	experiment	was	designed	to	measure	gene	expression	of	pro-inflammatory	 cytokines	 in	 CADASIL	 and	 control	 VSMCs.	 Pro-inflammatory	 gene	expression	in	CADASIL	VSMCs	was	overall	higher	compared	to	controls,	with	ICAM-1	and	IL-6	having	the	highest	expression.	Co-culturing	CADASIL	VSMCs	with	ECs	caused	ECs	to	have	a	higher	IL-12	and	IL-1	expression,	suggesting	that	CADASIL	VSMCs	cause	an	inflammatory	response	in	their	neighboring	cells.	This	project	is	still	in	its	infancy	and	we	 have	 planned	 on	 using	 frozen	 post	mortem	 brain	 tissues	 from	 CADASIL	 to	investigate	 cytokine	 levels	 in	 the	 brain.	 We	 will	 also	 investigate	 the	 number	 of	activated	microglial	 cells	 as	 a	 response	 to	 inflammatory	 elements	 in	 the	 brain.	We	hypothesize	 that	 we	 should	 see	 more	 activated	 microglia	 in	 close	 proximity	 to	cerebral	blood	vessels	in	CADASIL	tissue	as	VSMCs	produce	pro-inflammatory	signals.									In	these	studies,	we	have	tried	to	illustrate	the	multitude	of	events	that	can	occur	in	CADASIL	disease	progression.	Inhibition	of	any	one	of	these	events	has	the	potential	to	 slow	progression	of	 the	disease	or	even	halt	 progression.	However,	 these	 studies	are	 obviously	 preliminary	 and	 animal	 studies	 as	 well	 as	 VSMCs	 carrying	 other	CADASIL	mutations	are	needed	to	verify	and	further	strengthen	our	reports.	
 
6.1 LIMITATIONS OF THIS THESIS 	Although	CADASIL	is	generally	a	good	model	to	study	SVD,	it	is	difficult	to	work	with.	Throughout	 this	 thesis,	 many	 challenges	 arose	 that	 limited	 our	 ability	 to	 fully	investigate	this	disease	in	greater	detail.		One	of	the	more	difficult	tasks	we	encountered	was	that	VSMCs	are	hard	to	genetically	manipulate.	 We	 tried	 several	 transfection	 methods,	 including	 electroporation	 and	plasmid	 transfection,	but	 the	VSMCs	would	either	die	out	or	 lose	 the	plasmid	 insert	before	 stably	 expressing	 the	 mutated	 NOTCH3.	 We	 also	 noticed	 some	 subtle	differences	in	the	morphology	of	VSMCs	obtained	from	different	locations	in	the	body.	Aortic	VSMCs	were	generally	larger	and	exhibited	a	proliferation	rate	higher	than	that	of	umbilical	or	cerebral	VSMCs.			
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In	studies	where	we	used	post	mortem	tissues,	great	care	was	applied	to	find	gender-	and	age-matched	tissues.	However,	there	are	several	drawbacks	that	come	with	using	post	 mortem	 tissues.	 One	 problem	 is	 collection	 of	 brain	 tissue	 after	 death.	 Several	factors	 can	 affect	 the	 tissue,	 such	 as	 body	 temperature	before	 collection,	 time	 lapse	between	 time	 of	 death	 and	 collection,	 and	 fixation	 of	 the	 tissue.	 Many	 biochemical	events	occur	in	the	brain	at	death,	which	leads	to	degradation	of	tissues	and	release	of	chemicals	 that	 can	 alter	 experimental	 outcomes.	 Therefore,	 it	 is	 important	 that	 the	brain	 is	 harvested	 as	 soon	 as	 possible	 after	 death.	 Another	 caveat	 in	 using	 human	tissue	 in	CADASIL	 is	 that	many	variables	have	an	effect	on	 the	human	body	such	as	diet,	exercise,	drug	use,	and	other	lifestyle	choices	–	making	control	of	such	variables	impossible.	Even	with	the	challenges	stated	above,	human	tissue	 it	 is	still	one	of	 the	best	models	to	study	CADASIL.				In	 closing,	 as	 our	 understanding	 of	 CADASIL	 matures,	 additional	 questions	 arise	regarding	the	exact	mechanisms	of	pathology.	Our	work	over	the	past	 few	years	has	shed	light	on	several	aspects	of	CADASIL	that	have	not	been	previously	investigated,	and	 has	 implicated	 several	 processes	 that	may	 exacerbate	 disease	 progression.	 For	these	 reasons,	 it	 is	 important	 that	 continued	 studies	be	undertaken	 to	 elucidate	 the	mechanisms	underlying	CADASIL	disease	and	its	progression.		
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